Author: "Département de Dermatologie" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Département de Dermatologie"' showing total 772 results

Start Over Author "Département de Dermatologie"

772 results on '"Département de Dermatologie"'

1. Narrow resection margins are not associated with mortality or recurrence in patients with Merkel cell carcinoma: a retrospective study

Author: Eric Estève, Brigitte Dréno, Mahtab Samimi, Hervé Maillard, Yannick Le Corre, Agnès Caille, Astrid Blom, Monica Dinulescu, Philippe Saiag, Thibault Kervarrec, E. Wierzbicka-Hainaut, Frédéric Jaouen, Université de Tours (UT), Service de dermatologie, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Service de Pathologie [CHRU Tours], Infectiologie et Santé Publique (UMR ISP), Université de Tours (UT)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN)-Université de Nantes (UN), Centre d’Investigation Clinique [Tours] CIC 1415 (CIC ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de dermatologie [CHU Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de dermatologie [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de Dermatologie [Orléans], Centre Hospitalier Régional d'Orléans (CHRO), Département de Dermatologie [CHU Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service de dermatologie [CH Le Mans], Centre Hospitalier Le Mans (CH Le Mans), Service de Dermatologie [Rennes] = Dermatology [Rennes], CHU Pontchaillou [Rennes], Service de Dermatologie Générale et Oncologique [AP-HP Hôpital Ambroise-Paré, Paris], Hôpital Ambroise Paré [AP-HP], Université de Tours, Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Université de Tours-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), and CCSD, Accord Elsevier
Subjects: Male, Wide Local Excision, Neoplasm, Residual, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Cohort Studies, 030207 dermatology & venereal diseases, 0302 clinical medicine, Merkel cell carcinoma, Surgical margins, Wide local excision, Hazard ratio, Margins of Excision, Merkel Cell Carcinoma, Middle Aged, Prognosis, Combined Modality Therapy, Primary tumor, 3. Good health, [SDV] Life Sciences [q-bio], 030220 oncology & carcinogenesis, Cohort, Female, France, medicine.medical_specialty, [SDV.CAN]Life Sciences [q-bio]/Cancer, Dermatology, Disease-Free Survival, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, medicine, Humans, Mortality, General surgery, Survival rate, Aged, Proportional Hazards Models, Retrospective Studies, business.industry, Retrospective cohort study, [SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology, medicine.disease, Skin neoplasms, Survival Analysis, Surgery, Carcinoma, Merkel Cell, Radiation therapy, Multivariate Analysis, Radiotherapy, Adjuvant, Neoplasm Recurrence, Local, business, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, Follow-Up Studies
Abstract: Wide local excision constitutes the standard of care for Merkel cell carcinoma, but the optimal margin width remains controversial.To assess whether narrow margins (0.5-1 cm) were associated with outcome.Patients were recruited from a retrospective French multicentric cohort and included if they had had excision of primary tumor with minimum lateral margins of 0.5 cm. Factors associated with mortality and recurrence were assessed by multivariate regression.Among the 214 patients included, 58 (27.1%) had undergone excision with narrow margins (0.5-1 cm) versus 156 (72.9%) with wide margins (1 cm). During a median follow-up of 50.7 months, cancer-specific survival did not differ between groups (5-year specific survival rate 76.8% [95% confidence interval 61.7%-91.9%] and 76.2% [95% confidence interval 68.8%-83.6%], respectively). Overall survival, any recurrence-free survival, and local recurrence-free survival did not significantly differ between groups. Cancer-specific mortality was associated with age, male sex, American Joint Committee on Cancer stage III, and presence of positive margins.Retrospective design, heterogenous baseline characteristics between groups.Excision with narrow margins was not associated with outcome in this cohort, in which most patients had clear margins and postoperative radiation therapy. Residual tumor, mostly found on deep surgical margins, was independently associated with prognosis.
Published: 2021
Full Text: View/download PDF

2. Merkel cell polyomavirus‒negative Merkel cell carcinoma originating from in situ squamous cell carcinoma: a keratinocytic tumor with neuroendocrine differentiation

Author: Mahtab Samimi, Charline Nardin, Bhavishya Sarma, Yannick Le Corre, Astrid Blom, Eduardo Calonje, Eva-Maria Sarosi, Monica Dinulescu, Serge Guyétant, Guido Bens, Patricia Berthon, Soumanth Thanguturi, Roland Houben, Marion Wobser, Thibault Kervarrec, David Schrama, Ágnes Pekár-Lukacs, François Aubin, Antoine Touzé, Marie-Laure Jullie, Silke Appenzeller, Nathalie Benethon, Anne Tallet, Ewa Hainaut-Wierzbicka, Service de Pathologie [CHRU Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Infectiologie et Santé Publique (UMR ISP), Université de Tours (UT)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Department of Dermatology, Venerology and Allergology, Universitätsklinikum Würzburg, Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Service de dermatologie (CHRU de Tours), Département de dermatologie [CHU Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Département de Dermatologie [CHU Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service de dermatologie [CH Le Mans], Centre Hospitalier Le Mans (CH Le Mans), Service de Dermatologie [Orléans], Centre Hospitalier Régional d'Orléans (CHRO), Département de dermatologie, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Hôpital Saint-Jacques-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de Dermatologie [Rennes] = Dermatology [Rennes], CHU Pontchaillou [Rennes], Department of Oncology and Pathology [Lund], Lund University [Lund], St. John's Institute of Dermatology, King‘s College London, CHU Trousseau [Tours], Fondation ARC pour la recherche contre le cancer, Interdisziplinäres Zentrum für Klinische Forschung Würzburg (IZKF B-343), German Research Foundation (SCHR 1178/3-1), Ligue Nationale Contre le Cancer, Comités 16, 18, 28,HUGO Grant, Hôpital Ambroise Paré [AP-HP], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), and Université de Tours-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)
Subjects: Skin Neoplasms, Merkel cell polyomavirus, [SDV.CAN]Life Sciences [q-bio]/Cancer, Dermatology, Biology, medicine.disease_cause, Biochemistry, Neuroendocrine differentiation, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, Copy-number variation, Epigenetics, Molecular Biology, 030304 developmental biology, 0303 health sciences, Transition (genetics), Merkel cell carcinoma, food and beverages, Cell Biology, medicine.disease, biology.organism_classification, 3. Good health, Carcinoma, Merkel Cell, stomatognathic diseases, medicine.anatomical_structure, 030220 oncology & carcinogenesis, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Carcinoma, Squamous Cell, Cancer research, Merkel cell, Carcinogenesis, Carcinoma in Situ
Abstract: International audience; While virus-negative Merkel cell carcinoma (MCC) is characterized by high frequency of UV-induced mutations, expression of two viral oncoproteins is regarded as key mechanism driving Merkel cell polyomavirus (MCPyV)-positive MCC. The cells in which these molecular events initiate MCC oncogenesis have yet not been identified for both MCC subsets. A considerable proportion of virus-negative MCC is found in association with squamous cell carcinoma (SCC) suggesting (i) coincidental collision, (ii) one providing a niche for the other or (iii) one evolving from the other. Whole exome sequencing of four combined tumors consisting of SCC in situ and MCPyV-negative MCC demonstrated in all cases many mutations shared between SCC and MCC indicating a common ancestry and thereby a keratinocytic origin of these MCCs. Moreover, analyses of the combined cases as well as of pure SCC and MCC suggests that RB1 inactivation in SCC facilitates MCC development and that epigenetic changes may contribute to the SCC/MCC transition.
Published: 2021
Full Text: View/download PDF

3. Clinical and haemodynamic risk factors associated with discrepancies in lower limb length with capillary malformations: data from the national paediatric French cohort CONAPE

Author: Ali Dadban, Groupe de Recherche de la Société Française de Dermatologie Pédiatrique, C. Eschard, Christine Chiaverini, Nathalie Beneton, Sophie Leducq, Gérard Lorette, Olivia Boccara, Mahtab Samimi, Xavier Balguerie, Juliette Mazereeuw-Hautier, Patrice Plantin, Ludovic Martin, Pierre Vabres, Baptiste Morel, Sébastien Barbarot, Catherine Droitcourt, M Durieux-Verde, Agnès Caille, Didier Bessis, Annabel Maruani, Service de dermatologie (CHRU de Tours), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université Francois Rabelais [Tours], Centre d’Investigation Clinique [Tours] CIC 1415 (CIC ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de dermatologie (CHU de Toulouse), CHU Toulouse [Toulouse], Centre de référence national des Maladies Génétiques à Expression Cutanée (MAGEC), Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de dermatologie, CHU Angers, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de Dermatologie [Nice], Hôpital Archet 2 [Nice] (CHU), Service de dermatologie (CHU de Reims), Centre Hospitalier Universitaire de Reims (CHU Reims), Service de dermatologie [CH Le Mans], Centre Hospitalier Le Mans (CH Le Mans), Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de Dermatologie [Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Service de dermatologie et vénérologie [Hôpital Laënnec, site de Quimper], CH Cornouaille, Département de dermatologie [CHU de Montpellier], Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Service de dermatologie [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de dermatologie [CHU d'Amiens-Picardie], CHU Amiens-Picardie, Service de Dermatologie [Rennes] = Dermatology [Rennes], CHU Pontchaillou [Rennes], Service de radiographie pédiatrique (CHRU Tours), French Ministry of Social Affairs and Health (French National Program of Clinical Research [PHRC], 2009, Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Necker - Enfants Malades [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]
Subjects: Male, capillary malformations, medicine.medical_specialty, Duplex ultrasonography, Vascular Malformations, Radiography, Hemodynamics, Dermatology, 030204 cardiovascular system & hematology, Cohort Studies, lymphatic, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, port-wine-stains, medicine, Humans, Prospective Studies, Child, Prospective cohort study, overgrowth, geographic, venous, Leg, Ultrasonography, Doppler, Duplex, business.industry, medicine.disease, Parkes Weber syndrome, Capillaries, Leg Length Inequality, 3. Good health, Surgery, Child, Preschool, Overgrowth syndrome, Cohort, Female, Nuclear medicine, business, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, Blood Flow Velocity, Cohort study
Abstract: SummaryBackground Genetics discoveries have allowed for better understanding capillary malformations (CMs) with overgrowth syndrome. However, molecular analyses are still not easy to perform or interpret. Other analytical methods are needed. Objective We aimed to identify clinical and hemodynamic factors associated with leg length discrepancy (LLD) in children with CM of lower limbs. Methods Data were obtained from the multicentre French national cohort CONAPE (COhorte Nationale d'enfants atteints d'Angiome Plan de membrE inferieur), including children from 2 to 12 years old with CM of lower limbs. Clinical characteristics were prospectively collected. Hemodynamic factors were measured by an echographer who calculated the arterial blood flow (ABF) in both lower limbs. An ABF difference ≥50% between the two lower limbs was considered relevant. LLD ≥ 2% was determined by the same radiologist on centralized radiographs. Results We analyzed data at baseline for 96 children. The mean (SD) age was 5.6 (3.1) years; 49 (51%) were male; and 14 (15%) showed LLD. Thirty-two patients (33%) had venous anomalies, 13 (14%) lymphatic anomalies, and in 1 child, diagnosis of Parkes Weber syndrome was made. Only increased circumference above the knee was more frequent with than without LLD (50% vs 13%, p=0.02). In all, 10/79 patients (13%) showed a difference in ABF ≥50%: 4 had LLD. The frequency of differences in ABF ≥50% was greater with than without LLD [33.3% (n=4/12) vs 9.0% (n=6/67), p=0.04]. Conclusions ABF measured by Duplex ultrasonography is a simple, low-cost and non-invasive complementary examination for help in detecting LLD, with a difference ≥ 50% possibly associated. This article is protected by copyright. All rights reserved.
Published: 2018
Full Text: View/download PDF

4. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Author: Piotr Rutkowski, Lars Bastholt, Ralf Gutzmer, Claus Garbe, Virginia Ferraresi, Marta Nyakas, Omid Hamid, Joanna Pikiel, Jean-Jacques Grob, Paolo A. Ascierto, Céleste Lebbé, Caroline Robert, Delphine Hennicken, Vanna Chiarion-Sileni, Michael Smylie, Gabriella Liszkay, Florent Grange, Catriona M. McNeil, Luc Thomas, Dirk Schadendorf, Andrzej Mackiewicz, Michele Del Vecchio, Christoph Hoeller, Carmen Loquai, Michele Maio, Inge Marie Svane, Anila Qureshi, Brigitte Dréno, Ana Arance, Laurent Mortier, Istituto Nazionale Tumori Fondazione Pascale [Naples, Italy], Medical Oncology, National Cancer Institute [Milan, Italy], Institut Gustave Roussy ( IGR ), Department of Diagnostics and Cancer Immunology [Poznan, Poland], Greater Poland Cancer Centre [Poznan, Poland]-Poznan Medical University [Poland], Melanoma Oncology Unit [Padova, Italy], Veneto Institute of Oncology IOV-IRCCS [Padua, Italy], Institut d'Investigacions Biomèdiques August Pi I Sunyer [Barcelona, Spain] ( Hospital Clinic ), Immunologie, dermatologie, oncologie, Oncodermatologie, immunologie et cellules souches cutanées ( DIO U976 ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Odense University Hospital [Odense, Denmark], The Angeles Clinic and Research Institute [Los Angeles, CA, USA], Maria Sklodowska-Curie Memorial Cancer Center [Warsaw, Poland], Royal Prince Alfred Hospital ( RPAH - SYDNEY ), Melanoma Institute Australia [Sydney, NSW, Australia], Eberhard Karls University [Tübingen, Germany], University Medical Center [Mainz, Germany], Centre de Recherche en Cancérologie / Nantes - Angers ( CRCNA ), CHU Angers-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital Laennec-Centre National de la Recherche Scientifique ( CNRS ) -Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes ( CHU Nantes ), Département de Dermatologie [CH Lyon-Sud, Pierre-Bénite], Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Hôpital de la Timone [CHU - APHM] ( TIMONE ), National Institute of Oncology [Budapest, Hungary], Oslo University Hospital [Oslo, Norway], Medizinische Hochschule Hannover [Hannover, Germany], Wojewodzkie Centrum Oncologii [Gdańsk, Poland], Département de Dermatologie [CHU de Reims], Centre Hospitalier Universitaire de Reims ( CHU Reims ), Medical University of Vienna [Austria], Istituti Fisioterapici Ospitalieri [Rome, Italy], Cross Cancer Institute [Edmonton, AB, Canada], University Hospital [Essen, Germany], Hôspital Claude Huriez [Lille, France], Herlev Hospital [Herlev, Denmark], University of Copenhagen ( KU ), Bristol-Myers Squibb [Princeton, NJ, USA], Istituto Toscano Tumori [Siena, Italy], University Hospital of Siena [Italy], Bristol-Myers Squibb., Institut Gustave Roussy (IGR), Institut d'Investigacions Biomèdiques August Pi I Sunyer [Barcelona, Spain] (Hospital Clinic ), Oncodermatologie, immunologie et cellules souches cutanées (IDO (U976 / UMR_S 976)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Cedars-Sinai Medical Center, Royal Prince Alfred Hospital (RPAH - SYDNEY), Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Hôpital de la Timone [CHU - APHM] (TIMONE), Oslo University Hospital [Oslo], Centre Hospitalier Universitaire de Reims (CHU Reims), Medizinische Universität Wien = Medical University of Vienna, Hôpital Claude Huriez [Lille], CHU Lille, Herlev and Gentofte Hospital, Bristol-Myers Squibb [Princeton], and Bernardo, Elizabeth
Subjects: Male, 0301 basic medicine, Medizin, Gastroenterology, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, law.invention, 0302 clinical medicine, Randomized controlled trial, law, Clinical endpoint, Melanoma, education.field_of_study, Hazard ratio, Antibodies, Monoclonal, Alanine Transaminase, Middle Aged, Colitis, Intention to Treat Analysis, 3. Good health, Survival Rate, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Female, medicine.drug, Diarrhea, medicine.medical_specialty, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Antineoplastic Agents, Ipilimumab, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Double-Blind Method, Internal medicine, Journal Article, medicine, Humans, Hypophysitis, Adverse effect, education, Survival rate, Aged, Intention-to-treat analysis, business.industry, Surgery, 030104 developmental biology, business, Follow-Up Studies
Abstract: BACKGROUND: A phase 2 trial suggested increased overall survival and increased incidence of treatment-related grade 3-4 adverse events with ipilimumab 10 mg/kg compared with ipilimumab 3 mg/kg in patients with advanced melanoma. We report a phase 3 trial comparing the benefit-risk profile of ipilimumab 10 mg/kg versus 3 mg/kg.METHODS: This randomised, double-blind, multicentre, phase 3 trial was done in 87 centres in 21 countries worldwide. Patients with untreated or previously treated unresectable stage III or IV melanoma, without previous treatment with BRAF inhibitors or immune checkpoint inhibitors, were randomly assigned (1:1) with an interactive voice response system by the permuted block method using block size 4 to ipilimumab 10 mg/kg or 3 mg/kg, administered by intravenous infusion for 90 min every 3 weeks for four doses. Patients were stratified by metastasis stage, previous treatment for metastatic melanoma, and Eastern Cooperative Oncology Group performance status. The patients, investigators, and site staff were masked to treatment assignment. The primary endpoint was overall survival in the intention-to-treat population and safety was assessed in all patients who received at least one dose of study treatment. This study is completed and was registered with ClinicalTrials.gov, number NCT01515189.FINDINGS: Between Feb 29, and July 9, 2012, 727 patients were enrolled and randomly assigned to ipilimumab 10 mg/kg (365 patients; 364 treated) or ipilimumab 3 mg/kg (362 patients; all treated). Median follow-up was 14·5 months (IQR 4·6-42·3) for the ipilimumab 10 mg/kg group and 11·2 months (4·9-29·4) for the ipilimumab 3 mg/kg group. Median overall survival was 15·7 months (95% CI 11·6-17·8) for ipilimumab 10 mg/kg compared with 11·5 months (9·9-13·3) for ipilimumab 3 mg/kg (hazard ratio 0·84, 95% CI 0·70-0·99; p=0·04). The most common grade 3-4 treatment-related adverse events were diarrhoea (37 [10%] of 364 patients in the 10 mg/kg group vs 21 [6%] of 362 patients in the 3 mg/kg group), colitis (19 [5%] vs nine [2%]), increased alanine aminotransferase (12 [3%] vs two [1%]), and hypophysitis (ten [3%] vs seven [2%]). Treatment-related serious adverse events were reported in 133 (37%) patients in the 10 mg/kg group and 66 (18%) patients in the 3 mg/kg group; four (1%) versus two (INTERPRETATION: In patients with advanced melanoma, ipilimumab 10 mg/kg resulted in significantly longer overall survival than did ipilimumab 3 mg/kg, but with increased treatment-related adverse events. Although the treatment landscape for advanced melanoma has changed since this study was initiated, the clinical use of ipilimumab in refractory patients with unmet medical needs could warrant further assessment.FUNDING: Bristol-Myers Squibb.
Published: 2017
Full Text: View/download PDF

5. Sportifs en plein air, comparaison multisports des connaissances et comportements sur la protection solaire

Author: P. Thomas, Marc Jeanmougin, M. de Paula Correa, F. Aubin, Clément Roux, E. Mahé, Sophie Godin-Beekmann, J.-L. Schmutz, M.-A. Ionescu, A. Beauchet, Martine Avenel-Audran, V. Bellil, Service de Dermatologie et pathologies vasculaires [CH Argenteuil], Centre Hospitalier Victor Dupouy, Département de dermatologie [CHU Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de Dermatologie et Allergologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de Dermatologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de dermatologie (CHRU Besançon), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Département de Dermatologie [CHRU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Instituto de Recursos Naturais [Itajubá], Universidade Federal de Itajubá, STRATO - LATMOS, Laboratoire Atmosphères, Milieux, Observations Spatiales (LATMOS), Sorbonne Université (SU)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Sorbonne Université (SU)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS), Dermatological Laboratories of Uriage (URIAGE - Dermato), Laboratoires dermatologiques d'URIAGE, Herbiers universitaires de Clermont-Ferrand (UNIVEGE), Clermont Université, Hôpital Ambroise Paré [AP-HP], Service de Dermatologie - Centre Hospitalier Victor Dupouy, Fédération Hospitalière de France, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Département de dermatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut national des sciences de l'Univers (INSU - CNRS)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut national des sciences de l'Univers (INSU - CNRS)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)
Subjects: 030203 arthritis & rheumatology, [SDU.OCEAN]Sciences of the Universe [physics]/Ocean, Atmosphere, [PHYS.PHYS.PHYS-AO-PH]Physics [physics]/Physics [physics]/Atmospheric and Oceanic Physics [physics.ao-ph], 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Photo-protection, [SDV.CAN]Life Sciences [q-bio]/Cancer, Dermatology, Cancers cutanés, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, Sport
Abstract: Introduction La pratique de sports en plein air est associee a une exposition solaire intense et repetee. Ces sportifs presentent par ailleurs plus de marqueurs cutanes d’exposition solaire (naevus, keratoses actiniques…) et cancers cutanes. Peu de campagnes de prevention solaire ont ete developpees aupres de sportifs ou sur des populations tres ciblees (e.g., surfeurs). Pour etre efficace, une campagne en milieu sportif devrait cibler un sport populaire, expose et des sportifs ayant un comportement solaire inadapte. C’est pourquoi nous avons mene une comparaison « multisports » sur les connaissances du risque solaire et les comportements afin d’identifier les sports et athletes susceptibles d’etre la cible d’une telle campagne. Materiel et methodes Diffusion d’un flyer aupres d’associations sportives. Ce flyer proposait a tout sportif en plein air de participer a l’etude via un QR code ou une URL. Resultats Nous avons obtenu 406 reponses (hommes : 53,2 % ; âge moyen : 40,8 ans ; phototype III–IV : 79,1 %). Les sports les plus representes etaient : course a pied, triathlon, ski, golf et cyclisme. Les coups de soleil pendant le sport (75,9 %) etaient plus frequents chez les phototypes I a IV (p Discussion Cette etude observationnelle nous a permis d’identifier l’importance des campagnes de prevention a initier chez les sportifs jeunes pratiquant la competition, avec 2 disciplines qui semblent ressortir, le triathlon et le cyclisme. Une etude aupres des clubs et federations est en cours pour etudier la faisabilite de telles campagnes.
Published: 2020
Full Text: View/download PDF

6. Produits de protection solaire : utilisation, freins et axes à améliorer pour une meilleure observance chez les sportifs

Author: E. Mahé, Sophie Godin-Beekmann, M.-A. Ionescu, J.-L. Schmutz, V. Bellil, Martine Avenel-Audran, M. de Paula Correa, Marc Jeanmougin, F. Aubin, P. Thomas, A. Beauchet, Centre Hospitalier Victor Dupouy, Département de dermatologie, CHU Angers, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de Dermatologie et Allergologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de Dermatologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de dermatologie (CHRU Besançon), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de dermatologie (CHRU de Lille), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Instituto de Recursos Naturais [Itajubá], Universidade Federal de Itajubá, STRATO - LATMOS, Laboratoire Atmosphères, Milieux, Observations Spatiales (LATMOS), Sorbonne Université (SU)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Sorbonne Université (SU)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS), Dermatological Laboratories of Uriage (URIAGE - Dermato), Laboratoires dermatologiques d'URIAGE, Hôpital Ambroise Paré [AP-HP], Département de dermatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut national des sciences de l'Univers (INSU - CNRS)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut national des sciences de l'Univers (INSU - CNRS)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)
Subjects: 030203 arthritis & rheumatology, 030207 dermatology & venereal diseases, 03 medical and health sciences, Prévention solaire, 0302 clinical medicine, Dermatology, Photodermatologie, Produits de protection solaire, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, Sports
Abstract: Introduction La pratique des sports en plein air est associee a une exposition solaire intense et repetee. Les sportifs presentent plus de cancers cutanes et marqueurs cutanes d’exposition solaire. Peu de campagnes de prevention ont ete developpees en France aupres des sportifs. Nous avons mene une etude « multisports » afin d’identifier les sports et les athletes susceptibles d’etre la cible d’une telle campagne. Les produits de protection solaire (PPS) sont en general sous utilises. Dans la 2e partie du travail nous nous sommes interesses a l’utilisation des PPS, les freins a leur utilisation et aux axes d’amelioration suggeres par les sportifs. Materiel et methodes Nous avons distribue a des sportifs et a leurs associations un depliant proposant de participer a l’etude. Le flyer permettait d’acceder a l’enquete via un QR code ou une URL. Des questions ciblees sur l’utilisation, les freins a leur utilisation, et les axes d’amelioration etaient inclues. Resultats Nous avons obtenu 406 reponses (H : 53,2 % ; âge moy : 40,8 ans) de sportifs pratiquant 14 sports en plein air, 39,7 % en competition ; 75,9 % des sportifs avaient eu des coups de soleil pendant le sport. Parmi les sportifs, seuls 24,6 % declaraient toujours utiliser des PPS si exposition pendant le sport (11 h–17 h, printemps-ete), plus chez les femmes (p Un indice de protection (IPS) tres eleve (50+) etait utilise par 60,6 % des sportifs, en preferant la texture creme/lait (82,5 %). Seuls 25,4 % en reappliquaient en cas d’exposition prolongee. Les principaux obstacles a leur utilisation etaient : « vous n’y pensez-pas » (64,8 %) ; « ce n’est pas pratique » (23,9 %) ou « agreable » pendant le sport (25,1 %), et enfin « vous ne trouvez pas utile d’en appliquer » (22,9 %). Les moyens d’optimiser l’utilisation des PPS seraient ameliorer la « facilite d’utilisation » (51,0 %), « adapter le format » au sport (25,4 %) et une « texture » adaptee (17,2 %). Le prix des PPS n’etait bloquant que pour 4,4 % des sportifs. Discussion Cette enquete nous a permis de confirmer la sous-utilisation des PPS chez les sportifs, avec des profils de patients : jeunes hommes, triathletes, pratiquant la competition. Ceci permet d’identifier les populations a cibler dans les campagnes de prevention solaire mais aussi les messages a repeter tels que la repetition des applications ou l’utilisation d’IPS adaptes (protection moyenne). Des messages concernent plus les industriels afin d’adapter les PPS a cette population : travail sur les formats et les aspects cosmetiques. Conclusion Les PPS ne sont qu’une part des mesures de protection solaire chez les sportifs, mais necessaire eu egard a la pratique des sports en plein air. Des axes d’amelioration pour leur utilisation sont identifies.
Published: 2019
Full Text: View/download PDF

7. Merkel cell carcinoma of lymph nodes without a skin primary tumor: A potential metastatic neoplasia associated with a brisk immune response

Author: Mahtab Samimi, Guido Bens, Thibault Kervarrec, Gaëlle Fromont, Eva Hainaut-Wierzbicka, J. Zaragoza, David Schrama, Yannick Le Corre, Patrick Michenet, Agnès Caille, Patricia Berthon, François Aubin, Serge Guyétant, Hervé Maillard, Roland Houben, Pauline Gaboriaud, Antoine Touzé, Infectiologie et Santé Publique (UMR ISP), Université de Tours (UT)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Régional d'Orléans (CHRO), Département de dermatologie [CHU Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Nantes Université (Nantes Univ), Département de Dermatologie [CHU Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Department of Dermatology (CHU Besançon), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Le Mans (CH Le Mans), University Hospital of Würzburg, Centre d’Investigation Clinique [Tours] CIC 1415 (CIC ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR des Sciences Pharmaceutiques et Biologiques (Nantes Université - UFR Pharmacie), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Service de dermatologie (CHRU de Tours), Université de Tours (UT), CCSD, Accord Elsevier, Service de Pathologie, Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Université de Tours-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Département de Dermatologie, Service de Dermatologie, Department of Dermatology, Venerology and Allergology, Universitätsklinikum Würzburg, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d’Investigation Clinique de Nantes (CIC Nantes), and Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes)
Subjects: Skin Neoplasms, [SDV]Life Sciences [q-bio], Dermatology, epithelial–mesenchymal transition, Merkel cell carcinoma without primary, 030207 dermatology & venereal diseases, 03 medical and health sciences, Merkel cell carcinoma, 0302 clinical medicine, Immune system, medicine, Biomarkers, Tumor, ZEB1, metastasis, Humans, ComputingMilieux_MISCELLANEOUS, business.industry, CD8, lymph node, medicine.disease, Primary tumor, 3. Good health, [SDV] Life Sciences [q-bio], Carcinoma, Merkel Cell, Merkel cell polyomavirus, 030220 oncology & carcinogenesis, Lymphatic Metastasis, Cancer research, Neoplasms, Unknown Primary, Lymph, Lymph Nodes, CD33, business
Abstract: International audience; No abstract available
Published: 2019
Full Text: View/download PDF

8. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

Author: A. Schoeffler, Ziad Reguiai, Audrey Lasek, Anne-Sophie Dillies, Jonathan Giovannelli, Nadia Raison-Peyron, Marie-Christine Ferrier le Bouedec, Aurélie Du Thanh, Sarah Faiz, Anne Dompmartin, Laurent Misery, Marie-Aleth Richard, J. Delaunay, Jean-Philippe Lacour, Sandrine Rappelle-Duruy, Jean-Philippe Arnault, Céline Podevin, Anne-Bénédicte Duval-Modeste, Jean-David Bouaziz, Angèle Soria, Amélie Walter-Lepage, Julien Sénéchal, Delphine Staumont-Sallé, François Aubin, Catherine Droitcourt, N. Bellon, Sébastien Barbarot, Stéphane Barete, Florence Tetart, Marie Jachiet, Emmanuel Mahé, Nathalie Beneton, Edouard Begon, Audrey Nosbaum, A. Valois, C. Morice, Service de Dermatologie, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Lille Inflammation Research International Center - U 995 (LIRIC), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Dermatologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Polyclinique Courlancy (PC), Polyclinique de Courlancy, Immunologie de l'allergie cutanée et vaccination – Immunology of skin allergy and vaccination, Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Saint Vincent de Paul de Lille, Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL), Université catholique de Lille (UCL)-Université catholique de Lille (UCL), Université de Clermont-Ferrand, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de dermatologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de Dermatologie [Rouen], Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Service de dermatologie, Hôpital Augustin Morvan-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Département de dermatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service de Dermatologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Dermatologie [Rennes] = Dermatology [Rennes], CHU Pontchaillou [Rennes], CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service de dermatologie [CHU d'Amiens-Picardie], CHU Amiens-Picardie, Département de dermatologie, CHU Angers, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de Dermatologie et pathologies vasculaires [CH Argenteuil], Centre Hospitalier Victor Dupouy, Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Service de Dermatologie [Nice], Hôpital Archet 2 [Nice] (CHU), Centre Hospitalier René Dubos [Pontoise], CHU La Milétrie, Université de Picardie Jules Verne (UPJV), Service de Dermatologie, Hôpital Joseph Imbert, Centre Hospitalier d'Arles, CHU Pitié-Salpêtrière [AP-HP], Service de dermatologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Le Mans (CH Le Mans), Hôpital d'Instruction des Armées Sainte Anne, Service de Santé des Armées, Neurofibromatosis Clinic, Centre hospitalier universitaire de Nantes (CHU Nantes), Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), CCSD, Accord Elsevier, Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Groupe Hospitalier de l'Institut Catholique de Lille (GHICL), Normandie Université (NU)-Normandie Université (NU)-Hôpital Charles Nicolle [Rouen], Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Hôpital Augustin Morvan, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Hôpital Saint-Jacques-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Adult, Male, medicine.medical_specialty, Injections, Subcutaneous, [SDV]Life Sciences [q-bio], Kaplan-Meier Estimate, Dermatology, Antibodies, Monoclonal, Humanized, Risk Assessment, Severity of Illness Index, Eczema Area and Severity Index, Drug Administration Schedule, Dermatitis, Atopic, Cohort Studies, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Interquartile range, Internal medicine, dupilumab, medicine, conjunctivitis, Humans, SCORAD, Adverse effect, Proportional Hazards Models, Retrospective Studies, Dose-Response Relationship, Drug, medicine.diagnostic_test, business.industry, Antibodies, Monoclonal, Atopic dermatitis, Dermatology Life Quality Index, medicine.disease, adultsatopic dermatitis, Dupilumab, 3. Good health, [SDV] Life Sciences [q-bio], 030220 oncology & carcinogenesis, Cohort, biotherapy, Female, France, Patient Safety, business, eosinophilia
Abstract: International audience; BackgroundDupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials.ObjectiveWe sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort.MethodsWe included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up.ResultsWe included 241 patients. The median ± interquartile range (IQR) follow-up time was 3.8 ± 3.7 months. A ≥75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a ≥75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD ± IQR, 25 ± 21 vs 56 ± 27.4, P < 10−9 and EASI ± IQR, 4.1 ± 6.8 vs 17.9 ± 15.4, P < 10−9, respectively). Conjunctivitis was reported in 84 of 241 (38.2%) patients. The proportion with eosinophilia (>500 cells/mm3) during follow-up (57%) was higher than that at baseline (33.7%) (n = 172, P < 10−6). Dupilumab was stopped in 42 cases; 27 patients stopped because of AEs.LimitationsNo control group, missing data.ConclusionThis real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a higher frequency of conjunctivitis and eosinophilia.
Published: 2019
Full Text: View/download PDF

9. Projet Sport-UV : modélisation du risque solaire chez les sportifs

Author: Martine Avenel-Audran, P. Thomas, Laurent Meunier, M. Jeanmougin, A. Beauchet, V. Bellil, M. de Paula Correa, M.-A. Ionescu, Société française de photodermatologie, E. Mahé, Sophie Godin-Beekmann, J.-L. Schmutz, F. Aubin, Instituto de Recursos Naturais [Itajubá], Universidade Federal de Itajubá, STRATO - LATMOS, Laboratoire Atmosphères, Milieux, Observations Spatiales (LATMOS), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut national des sciences de l'Univers (INSU - CNRS)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut national des sciences de l'Univers (INSU - CNRS)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Dermatological Laboratories of Uriage (URIAGE - Dermato), Laboratoires dermatologiques d'URIAGE, Département de dermatologie, CHU Angers, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de Dermatologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Dermatologie et Allergologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Département de dermatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre Hospitalier Universitaire de Lille (CHU de Lille), Hôpital Ambroise Paré [AP-HP], Service de Dermatologie - Centre Hospitalier Victor Dupouy, Fédération Hospitalière de France, PRES Université Nantes Angers Le Mans (UNAM), CHU Lille, Centre Hospitalier Victor Dupouy, Sorbonne Université (SU)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Sorbonne Université (SU)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS), Service de dermatologie (CHRU Besançon), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), and Cardon, Catherine
Subjects: [PHYS.PHYS.PHYS-AO-PH]Physics [physics]/Physics [physics]/Atmospheric and Oceanic Physics [physics.ao-ph], Risques solaires, Vitamine D, Dermatology, [SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology, [PHYS.PHYS.PHYS-AO-PH] Physics [physics]/Physics [physics]/Atmospheric and Oceanic Physics [physics.ao-ph], [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, Sport
Abstract: Introduction Le projet Sport-UV est une collaboration entre physiciens et dermatologues menee en 3 etapes :. – evaluer le risque solaire chez les sportifs - modelisation du risque et etude des comportements ; – sensibilisation de cette cible ; – etude interventionnelle. Nous presentons ici les resultats de la modelisation des doses d’ultraviolets (UV) erythemales (DE) et de vitamine D (DD) synthetisee par des sujets pratiquant du sport en plein air dans 3 villes, Paris, Marseille et Brest. Materiel et methodes Les modelisations des DE et DD ont ete calculees a partir des donnees climatologiques et des contenus d’ozone en France. Les calculs ont pris en compte : periodes, jours/heures d’exposition, angles d’exposition de la peau, phototypes, surface cutanee exposee et nebulosite. Resultats Pendant les journees d’ete, en situations de ciel clair, les DE a midi peuvent atteindre des valeurs superieures a 800 Jm−2. Ces quantites sont suffisantes pour le developpement d’un erytheme chez des individus de phototype V (DE > 600 Jm−2) en moins d’une heure. Les doses maximales cumulees pendant toute la journee ont varie entre 4,6 a 5,5 kJm−2 selon les variabilites naturelles de la couche d’ozone. Pour les 3 villes etudiees, les DE calculees etaient superieures a 10 SED, 8 mois sur 12. Marseille presente des quantites de rayonnement UV significativement plus elevees que celles observees a Paris ou Brest. Ces doses sont calculees pour des surfaces a l’horizontale. Sur une surface a 30°, le sujet recoit 89 % de rayonnement UV ; sur une surface a 60°, elle tombe a 63 %. Les nuages impactent la quantite d’UV selon le type et le taux de couverture. Nos simulations ont montre des attenuations > 60 %. Pour atteindre la synthese de 1000 UI de vit D pour un individu de phototype II avec exposition du visage, des mains et des bras, le temps varie entre 30 min (debut mars et fin septembre) a Discussion Nos resultats montrent que l’ensemble du territoire national est soumis a une irradiation UV relativement homogene, quel que soit le phototype. Pour les 3 villes etudiees, les DE calculees etaient importantes et comparables tout au long de l’annee, a l’exception de la periode novembre–fevrier. En raison des consequences clinicobiologiques de l’exposition UV, ces donnees doivent etre connues des sportifs et des professionnels exposes. En ce qui concerne la synthese epidermique de vitamine D, les quantites de rayonnement UV sont suffisantes et compatibles avec une duree d’exposition quotidienne realiste de mai a septembre. Conclusion Cette modelisation du risque est la 1ere etape du projet Sport-UV et montre la complexite des calculs et des parametres impliques. L’etude des comportements, en cours dans differents sports pratiques en plein air, permettra de mieux cibler les populations les plus « a risque » au sein des sportifs, avant realisation d’une etude interventionnelle.
Published: 2018
Full Text: View/download PDF

10. Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design

Author: Valérie Gissot, Laurent Guibaud, Groupe de Recherche de la Société Française de Dermatologie Pédiatrique, Jean-Baptiste Woillard, Christine Chiaverini, Sébastien Barbarot, Catherine Droitcourt, Stéphanie Mallet, Bruno Giraudeau, Juliette Mazereeuw-Hautier, Dominique Goga, Ludovic Martin, Gérard Lorette, Jérôme Rollin, Denis Herbreteau, Didier Bessis, Yves Gruel, Baptiste Morel, Annabel Maruani, Sophie Leducq, Annie-Pierre Jonville-Béra, Anne Le Touze, Elsa Tavernier, Pierre Vabres, Olivia Boccara, Sophie Blaise, MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN)-Université de Nantes (UN), Service de dermatologie (CHRU de Tours), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Clinical Investigation Center - INSERM 1415, CHU Necker - Enfants Malades [AP-HP], Centre de Référence National des Maladies Génétiques à Expression Cutanée (MAGEC), Service de Dermatologie, Département de dermatologie [CHU de Montpellier], Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de dermatologie (CHU de Toulouse), CHU Toulouse [Toulouse], Service de dermatologie [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de Dermatologie [Nice], Hôpital Archet 2 [Nice] (CHU), Clinique de Médecine Vasculaire, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Service de Dermatologie [Rennes], CHU Pontchaillou [Rennes], Département de dermatologie, CHU Marseille, CHU Marseille, Service de Dermatologie [CHU Angers] (PXE - le PseudoXanthome Elastique), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de pharmacologie clinique [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Groupe innovation et ciblage cellulaire (GICC), EA 7501 [2018-...] (GICC EA 7501), Université de Tours, Service de neuroradiologie [Tours], Service de chirurgie maxillo-faciale [CHRU Tours], Département de chirurgie pédiatrique [Clocheville University Hospital, Tours], CHRU Clocheville, CIC 1415 Centre d’Investigation Clinique, Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Radiologie [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université-Sorbonne Université, Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Centre d’Investigation Clinique [Tours] CIC 1415 (CIC ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de dermatologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital Femme Mère Enfant [CHU - HCL] (HFME), Hospices Civils de Lyon (HCL), CHU Dijon, Centre Hospitalier Universitaire [Grenoble] (CHU), PRES Université Nantes Angers Le Mans (UNAM), Pharmacologie des Immunosuppresseurs et de la Transplantation (PIST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Université de Limoges (UNILIM)-CHU Limoges, Université de Tours (UT), Groupe de Recherche de la Societé Française de Dermatologie Pédiatrique., Rollin, Jérôme, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Limoges (UNILIM)-CHU Limoges-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Male, Pediatrics, Time Factors, Vascular Malformations, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Medicine (miscellaneous), Study Protocol, 0302 clinical medicine, Quality of life, Sclerotherapy, Clinical endpoint, Multicenter Studies as Topic, Pharmacology (medical), Child, Lymphatic malformations, Children, Mammalian target of rapamycin inhibitors, Randomized Controlled Trials as Topic, lcsh:R5-920, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Age Factors, Vascular anomalies, Magnetic Resonance Imaging, 3. Good health, Lymphangiogenesis, Natural history, [SDV] Life Sciences [q-bio], Observational Studies as Topic, Treatment Outcome, 030220 oncology & carcinogenesis, Venous malformations, Female, France, lcsh:Medicine (General), Blood Flow Velocity, medicine.drug, medicine.medical_specialty, Adolescent, 03 medical and health sciences, Clinical Trials, Phase II as Topic, 030225 pediatrics, Coronary Circulation, medicine, Humans, Protein Kinase Inhibitors, Sirolimus, business.industry, Clinical trial, Randomized placebo-phase design, Observational study, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: Background Slow-flow superficial vascular malformations (VMs) are rare congenital anomalies that can be responsible for pain and functional impairment. Currently, we have no guidelines for their management, which can involve physical bandages, sclerotherapy, surgery, anti-inflammatory or anti-coagulation drugs or no treatment. The natural history is progressive and worsening. Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that acts as a master switch in cell proliferation, apoptosis, metabolism and angio/lymphangiogenesis. Sirolimus directly inhibits the mTOR pathway, thereby inhibiting cell proliferation and angio/lymphangiogenesis. Case reports and series have reported successful use of sirolimus in children with different types of vascular anomalies, with heterogeneous outcomes. Objective The objective of this trial is to evaluate the efficacy and safety of sirolimus in children with complicated superficial slow-flow VMs. Methods/design This French multicenter randomized observational-phase, phase 2 trial aims to include 50 pediatric patients 6 to 18 years old who have slow-flow (lymphatic, venous or lymphatico-venous) voluminous complicated superficial VM. Patients will be followed up for 12 months. All patients will start with an observational period (no treatment). Then at a time randomly selected between month 4 and month 8, they will switch to the experimental period (switch time), when they will receive sirolimus until month 12. Each child will undergo MRI 3 times: at baseline, at the switch time, and at month 12. For both periods (observational and treatment), we will calculate the relative change in volume of the VM divided by the study period duration. This relative change weighted by the study period duration will constitute the primary endpoint. VM will be measured by MRI images, which will be centralized and interpreted by the same radiologist who will be blinded to the study period. Hence, each patient will be his/her own control. Secondary outcomes will include assessment of safety and efficacy by viewing standardized digital photographs and according to the physician, the patient or proxy; impact on quality of life; and evolution of biological makers (coagulation factors, vascular endothelial growth factor, tissue factor). Discussion The main benefit of the study will be to resolve uncertainty concerning the efficacy of sirolimus in reducing the volume of VMs and limiting related complications and the safety of the drug in children with slow-flow VMs. This trial design is interesting in these rare conditions because all included patients will have the opportunity to receive the drug and the physician can maintain it after the end of the protocol if is found efficient (which would not be the case in a classical cross-over study). Trial registration ClinicalTrials.gov Identifier: NCT02509468, first received: 28 July 2015. EU Clinical Trials Register EudraCT Number: 2015-001096-43. Electronic supplementary material The online version of this article (10.1186/s13063-018-2725-1) contains supplementary material, which is available to authorized users.
Published: 2018
Full Text: View/download PDF

11. Epidermolysis bullosa simplex generalized severe induces a Th17 response and is improved by Apremilast treatment

Author: E. Castela, Christine Chiaverini, Frédéric Bérard, Fanny Morice-Picard, J.-P. Lacour, Didier Bessis, Jean-François Nicolas, Aurore Rozières, Meri K. Tulic, D. Baty, Jean Kanitakis, Pierre Vabres, J. Mazereeuw, Thierry Passeron, Emmanuelle Bourrat, Service de Dermatologie [Nice], Hôpital Archet 2 [Nice] (CHU), Immunologie de l'allergie cutanée et vaccination – Immunology of skin allergy and vaccination, Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Inserm U1065, Centre Méditerranéen de Médecine Moléculaire, Centre de référence national des Maladies Génétiques à Expression Cutanée - National Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département d'allergie et d'immunologie clinique [CHU Lyon Sud], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Département de Dermatologie [CH Lyon-Sud, Pierre-Bénite], Infections Virales et Pathologie Comparée - UMR 754 (IVPC), Institut National de la Recherche Agronomique (INRA)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Département de dermatologie [CHU de Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Bordeaux [Bordeaux], Ninewells Hospital and Medical School [Dundee], Centre de Référence des Epidermolyses Bulleuses Héréditaires [Nice] (CREBHN), Centre Hospitalier Universitaire de Nice (CHU Nice), Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de référence national des Maladies Génétiques à Expression Cutanée (MAGEC), CHU Necker - Enfants Malades [AP-HP]-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Institut National de la Recherche Agronomique (INRA)-École pratique des hautes études (EPHE)-Université Claude Bernard Lyon 1 (UCBL), Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), CHU Toulouse [Toulouse], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], and Institut National de la Recherche Agronomique (INRA)-École pratique des hautes études (EPHE)
Subjects: Adult, Male, Pathology, medicine.medical_specialty, Inflammation, Pilot Projects, Dermatology, Pathogenesis, 030207 dermatology & venereal diseases, 03 medical and health sciences, Epidermolysis bullosa simplex, Young Adult, 0302 clinical medicine, medicine, CXCL10, Humans, Child, Retrospective Studies, Skin, integumentary system, business.industry, Anti-Inflammatory Agents, Non-Steroidal, Infant, Newborn, Keratin-14, Infant, Middle Aged, medicine.disease, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, 3. Good health, Thalidomide, Treatment Outcome, Child, Preschool, Epidermolysis Bullosa Simplex, Mutation, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, CXCL9, Keratin-5, Th17 Cells, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, Apremilast, medicine.symptom, business, Infiltration (medical), Immunostaining, medicine.drug
Abstract: International audience; BACKGROUND: Epidermolysis bullosa simplex generalized severe is a genetic disorder caused by mutation in KRT5 or KRT14 genes. Usually considered as a mechanical disease, recent data argue for additional inflammatory mechanisms. OBJECTIVES: The aim of this study was to assess the inflammation in the skin of patients with EBS. METHODS: A first immunohistochemical retrospective study was performed on frozen skin samples from 17 EBS-gen sev patients. A second multicenter prospective study was conducted on 10 patients with severe EBS-gen sev. Blister fluid and epidermis were processed for immunochemistry analysis and quantitative real time PCR. Cytokine expression was analyzed in blister fluid and compared with controls. RESULTS: Histological analysis showed a constant dermal perivascular CD4+ lymphocytes infiltrate in skin biopsies of blister (n=17) as well as in rubbed skin (n=5), an epidermal infiltration of neutrophils and eosinophils in 70% of cases and an increased immunostaining for CXCL9 and CXCL10 in blistering skin. High levels of Th17 cytokines were detected in lesional skin. Three adult patients with EBS-gen sev were treated with apremilast with a dramatic improvement of skin blistering and good tolerance. CONCLUSION: Our study demonstrates the importance of inflammation in EBS-gen sev patients and underlines the key role for Th17 cells in its pathogenesis. In addition, this study provides promising new therapeutic approaches for this disabling disorder. This article is protected by copyright. All rights reserved.
Published: 2018
Full Text: View/download PDF

12. Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma

Author: Mona Amini-Adle, Pierre Marcant, Yannick Le Corre, Caroline Dutriaux, Nora Kramkimel, Anne Bénédicte Duval Modeste, N. Litrowski, C. Lesage, Nicolas Meyer, Amir Khammari, Caroline Gaudy-Marqueste, C. Mignard, Aurélie Deschamps Huvier, Eve Maubec, Thierry Lesimple, Laurent Mortier, Florence Brunet-Possenti, L. Visseaux, Géraldine Jeudy, A. Stefan, Marie-Françoise Avril, Sabiha Trabelsi, Henri Montaudié, François Aubin, Pascal Joly, Laurent Machet, André Gillibert, Marie-Thérèse Leccia, Jean-Philippe Arnault, Nathalie Beneton, E. Wierzbicka-Hainaut, Dan Lipsker, Service de dermatologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), CHU Bordeaux [Bordeaux], Clinical and Translational Research in Skin Cancer (CRCINA-ÉQUIPE 2), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Service de Dermatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Cochin [AP-HP], Hôpital Claude Huriez [Lille], CHU Lille, Département d'oncologie médicale [Rennes], CRLCC Eugène Marquis (CRLCC), Département de dermatologie, CHU Marseille, CHU Marseille, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de dermatologie (CHRU de Tours), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Département de dermatologie, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Hôpital Saint-Jacques-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Département de la santé publique [CHU Strasbourg], CHU Strasbourg, Centre Hospitalier Le Mans (CH Le Mans), Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de dermatologie [CHU d'Amiens-Picardie], CHU Amiens-Picardie, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Service de dermatologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Service de Dermatologie, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Dermatology Department, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Département Pluridisciplinaire de Médecine, Dermatologie, CHU Grenoble-Hôpital Michallon, Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Saint-André, Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Université Paris Descartes - Paris 5 (UPD5), Hôpital de la Timone [CHU - APHM] (TIMONE), Université Francois Rabelais [Tours], Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire de Nice (CHU Nice), Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Hospitalier Universitaire [Grenoble] (CHU), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Hôpital Avicenne [AP-HP], Université Paris 13 (UP13), PRES Université Nantes Angers Le Mans (UNAM), Université de Strasbourg (UNISTRA), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Groupe Hospitalier du Havre Hôpital Jacques Monod (MONTIVILLIERS) (GHH), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), and TAN, Yossan-Var
Subjects: 0301 basic medicine, medicine.medical_specialty, Article Subject, medicine.medical_treatment, Gastroenterology, lcsh:RC254-282, 03 medical and health sciences, 0302 clinical medicine, Interquartile range, Internal medicine, medicine, Stage (cooking), Chemotherapy, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, business.industry, Melanoma, Mucosal melanoma, Retrospective cohort study, Immunotherapy, [SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 3. Good health, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Cohort, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, Research Article
Abstract: Background: The objective was to assess the response rate and survival of patients with metastatic mucosal melanoma (MM) and uveal melanoma (UM) treated with anti-CTLA-4 or anti-PD-1 monoclonal antibodies (mAbs).Methods: A multicenter retrospective study was performed in 25 dermatology departments in France. All patients with stage III-C to IV MM or UM who were treated with anti-CTLA-4 or anti-PD-1 mAbs between 2008 and 2016 were included and compared after adjustment for main prognostic factors with a second cohort of patients treated with chemotherapy. Tumor response was evaluated according to RECIST v. 1.1 criteria at Week 12.Results: Four-hundred-and-thirty-nine patients were included, 229 MM (151 immunotherapy, 78 chemotherapy) and 210 UM (100 immunotherapy, 110 chemotherapy). Response rates of MM patients treated with immunotherapy were 18/151 (11.9%; 95% CI:7.2%-18.2%), versus 11/78 (14.1%, 95% CI:7.3%-23.8%) in patients treated with chemotherapy (p=0.87). No tumor response was observed in UM patients treated with immunotherapy, versus 4/110 responses (3.6%, 95% CI:1.0-9.0%) in patients treated with chemotherapy (p=0.15). The adjusted overall survival (OS) of MM patients treated with immunotherapy was longer than that of patients treated with chemotherapy HR=0.62 (95% CI: 0.43-0.91), p=0.014, with an unadjusted median OS of 15.97 months [interquartile range (IQR)=6.89-27.11] and 8.82 months [IQR=5.02-14.92], respectively. The adjusted OS of UM patients treated with immunotherapy was not significantly different from that of patients treated with chemotherapy (HR=0.98, 95% CI: 0.66-1.44) p=0.92, with an unadjusted median OS of 13.38 months [IQR=6.03-29.57] and 11.02 months [IQR=6.13-23.93], respectively.Conclusion: Immunotherapy significantly improves OS for MM. The prognosis of metastatic UM remains poor., Immunotherapy significantly improves OS for MM. The prognosis of metastatic UM remains poor.
Published: 2018
Full Text: View/download PDF

13. A novel anti-CD146 antibody specifically targets cancer cells by internalizing the molecule

Author: Nollet, Marie, STALIN, JIMMY, Moyon, Anaïs, Traboulsi, Wael, Essaadi, Amel, Robert, Stéphane, Malissen, Nausicaa, Bachelier, Richard, Daniel, Laurent, Foucault-Bertaud, Alexandrine, Gaudy-Marqueste, Caroline, Lacroix, Romaric, Leroyer, Aurélie, Guillet, Benjamin, Bardin, Nathalie, Dignat-George, Francoise, Blot-Chabaud, Marcel, Vascular research center of Marseille (VRCM), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie de l'Endothelium, Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Aix-Marseille Université - Faculté de pharmacie (AMU PHARM), Aix Marseille Université (AMU), Département de dermatologie [CHU de Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital de la Timone [CHU - APHM] (TIMONE), Département de dermatologie, CHU Marseille, CHU Marseille, Laboratoire d'Immunologie [Hôpital de la Conception - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), and Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )
Subjects: therapy, PET, CD146, antibody, [SDV]Life Sciences [q-bio], cancer, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; CD146 is an adhesion molecule present on many tumors (melanoma, kidney, pancreas, breast, ...). In addition, it has been shown to be expressed on vascular endothelial and smooth muscle cells. Generating an antibody able to specifically recognize CD146 in cancer cells (designated as tumor CD146), but not in normal cells, would thus be of major interest for targeting tumor CD146 without affecting the vascular system. We thus generated antibodies against the extracellular domain of the molecule produced in cancer cells and selected an antibody that specifically recognizes tumor CD146. This antibody (TsCD146 mAb) was able to detect CD146-positive tumors in human biopsies and in vivo, by PET imaging, in a murine xenograft model. In addition, TsCD146 mAb antibody was able to specifically detect CD146-positive cancer microparticles in the plasma of patients. TsCD146 mAb displayed also therapeutic effects since it was able to reduce the growth of human CD146-positive cancer cells xenografted in nude mice. This effect was due to a decrease in the proliferation and an increase in the apoptosis of CD146-positive cancer cells after TsCD146-mediated internalization of the cell surface CD146. Thus, TsCD146 mAb could be of major interest for diagnostic and therapeutic strategies against CD146-positive tumors in a context of personalized medicine. www.impactjournals.com/oncotarget/
Published: 2017
Full Text: View/download PDF

14. Characteristics of patients with plaque psoriasis who have discordance between Psoriasis Area Severity Index and dermatology life quality index scores

Author: Eric Esteve, François Maccari, D. Bouilly-Auvray, N. Quiles-Tsimaratos, M-L Sigal, T. Le Guyadec, Christian Girard, Z. Reguiai, M. Amy de la Bretèque, C. Pauwels, M. Ruer-Mulard, E. Mahé, Gem Resopso, A. Beauchet, Martine Avenel-Audran, Matthieu Bastien, Service de Dermatologie et pathologies vasculaires [CH Argenteuil], Centre Hospitalier Victor Dupouy, Hôpital Ambroise Paré [AP-HP], Hôpital Saint-Joseph [Marseille], Centre Hospitalier Régional d'Orléans (CHRO), Hôpital d'instruction des Armées Percy, Service de Santé des Armées, Hôpital d'Instruction des Armées Begin, Département de Dermatologie [CHU de Reims], Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Département de dermatologie, CHU Angers, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), and CHI Poissy-Saint-Germain
Subjects: Adult, Male, medicine.medical_specialty, Index (economics), Dermatology, Severity of Illness Index, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Psoriasis, Sickness Impact Profile, Medicine, Humans, ComputingMilieux_MISCELLANEOUS, Plaque psoriasis, business.industry, Dermatology Life Quality Index, Middle Aged, medicine.disease, Infectious Diseases, 030220 oncology & carcinogenesis, Quality of Life, Female, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience
Published: 2017
Full Text: View/download PDF

15. Guidelines for the management of acne: recommendations from a French multidisciplinary group

Author: Viet-Thi Tran, P. Berger, Anne Bachelot, P. Henry, F. Beer, O. Romain, S. Brugère, G. Do-Pham, J. Gand-Gavanou, Tristan Ferry, Bernard Guillot, Annabel Maruani, O. Join-Lambert, M. Chastaing, B. Guigues, Bruno Sassolas, L. Le Cleach, E. Lavie, Bénédicte Lebrun-Vignes, R. Khallouf, Département de dermatologie, hôpital Henri Mondor, CHU Henri Mondor, Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de référence des maladies endocriniennes rares de la croissance et du développement [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Dermatologue, Collège de Gynécologie de Bordeaux et du Sud-Ouest, CHRU Brest - Psychiatrie Adulte (CHU - Brest- Psychiatrie), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Pathogénie des Staphylocoques – Staphylococcal Pathogenesis (StaPath), Centre International de Recherche en Infectiologie - UMR (CIRI), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), CIC - Mère Enfant Necker Cochin Paris Centre (CIC 1419), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Haute Autorité de Santé [Saint-Denis La Plaine] (HAS), Département de dermatologie, Université médicale de Vienne, Autriche, Hôpital Antoine Béclère, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Hôpital de la Cavale Blanche, Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de dermatologie [CHU de Montpellier], Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Henri Mondor [Créteil], Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Pitié-Salpêtrière [APHP], Centre de référence des maladies endocriniennes rares de la croissance [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Pathogénie des Staphylocoques – Staphylococcal Pathogenesis, CHU Cochin [AP-HP]-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)
Subjects: medicine.medical_specialty, [SDV]Life Sciences [q-bio], MEDLINE, Dermatology, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Patient Education as Topic, Multidisciplinary approach, Acne Vulgaris, Medicine, Humans, 030212 general & internal medicine, Acne, ComputingMilieux_MISCELLANEOUS, Evidence-Based Medicine, business.industry, Guideline adherence, Evidence-based medicine, medicine.disease, Hormones, Anti-Bacterial Agents, Family medicine, Practice Guidelines as Topic, France, Guideline Adherence, business
Abstract: International audience
Published: 2017
Full Text: View/download PDF

16. Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity

Author: Ugo Scemama, Jean-Jacques Grob, Jennifer Cautela, Marc Laine, Michael Peyrol, Alexis Jacquier, Marion Escudier, Franck Paganelli, Fabrice Barlesi, Johan Pinto, Jeremie Barraud, Ariel Cohen, Franck Thuny, N. Malissen, Laurent Bonello, Yann Ancedy, Nathalie Lalevée, Stéphane Ederhy, Sandrine Monestier, Morgane Orabona, Aix Marseille Université (AMU), Hôpital Nord [CHU - APHM], Département de dermatologie [CHU de Montpellier], Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Thrombose, atherothrombose et pharmacologie appliquée, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital de la Timone [CHU - APHM] (TIMONE), Département de dermatologie, CHU Marseille, CHU Marseille, Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Technologies avancées pour le génôme et la clinique (TAGC), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie de l'Endothelium, Vascular research center of Marseille (VRCM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Service de Cardiologie [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Oncologie multidisciplinaire et innovations thérapeutiques [Hôpital Nord - APHM], Aix Marseille Université (AMU)- Hôpital Nord [CHU - APHM]-Assistance Publique - Hôpitaux de Marseille (APHM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM]
Subjects: Adult, Male, medicine.medical_specialty, Time Factors, Databases, Factual, Heart Diseases, Cardiology, [SDV.CAN]Life Sciences [q-bio]/Cancer, 030204 cardiovascular system & hematology, Risk Assessment, Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Risk Factors, Informed consent, Allergy and Immunology, Neoplasms, Physiology (medical), medicine, Humans, Intensive care medicine, Adverse effect, Aged, Retrospective Studies, Aged, 80 and over, Cardiotoxicity, business.industry, Medical record, Incidence (epidemiology), Cancer, Middle Aged, Institutional review board, medicine.disease, 3. Good health, Clinical trial, 030220 oncology & carcinogenesis, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Female, Cardiology and Cardiovascular Medicine, business
Abstract: Immune checkpoint inhibitors (ICIs) represent a major advance in the treatment of cancer. Although clinical trials reported a low incidence of immune-related cardiovascular adverse events,1 the number of published life-threatening cases of cardiotoxicity is increasing.2 In this descriptive observational analysis, we aimed to describe the clinical manifestations, management, and outcomes of patients who developed ICI-related cardiotoxicity. The medical records of patients with a clinical suspicion of ICI-related cardiotoxicity were reviewed from the databases of 2 cardio-oncology units between March 2015 and April 2017. The patients are managed according to similar protocols. Because no specific follow-up had previously been established for patients receiving ICIs during the study period, the oncologists referred patients receiving ICIs only on the basis of their clinical suspicion of cardiovascular events. These patients had a standardized evaluation including clinical consultation, ECG, transthoracic echocardiography, and measurement of brain natriuretic peptide and troponin I serum levels. The management of cardiotoxicity was left to the physician’s discretion. The study was approved by our institutional review board, and informed consent has been obtained from the subjects. To create a pooled analysis, we also searched PubMed for English articles reporting cases of ICI-related cardiotoxicity until April 2017. We selected …
Published: 2017
Full Text: View/download PDF

17. Prognostic value of antibodies to Merkel cell polyomavirus T antigens and VP1 protein in patients with Merkel cell carcinoma

Author: Serge Guyétant, Flore Rozenberg, A. Carlotti, Eric Estève, Martine Avenel-Audran, Gérard Lorette, Eve Maubec, Antoine Touzé, François Aubin, Mahtab Samimi, E. Wierzbicka-Hainaut, Nicolas Dupin, Nathalie Beneton, L. Molet, Marie-Françoise Avril, C. Gardair, Hélène Laude, M. Baudin, Pierre Coursaget, Maxime Fleury, L. Gouguet, Service de dermatologie (CHRU de Tours), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Groupe d'Etude des Interactions Hôte-Parasite (GEIHP), Université d'Angers (UA), Laboratoire d'Oncologie Virale, Centre National de la Recherche Scientifique (CNRS), Département de dermatologie, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), Département de dermatologie, CHU Angers, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de dermatologie (CH Le Mans), Centre Hospitalier Le Mans (CH Le Mans), Service de dermatologie (CHRU Besançon), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Calcul Thermodynamique, Institut de Mécanique et d'Ingénierie de Bordeaux (I2M), École Nationale Supérieure d'Arts et Métiers (ENSAM), Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-Institut Polytechnique de Bordeaux-Institut National de la Recherche Agronomique (INRA)-Centre National de la Recherche Scientifique (CNRS)-Université de Bordeaux (UB), Université Francois Rabelais [Tours], Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service de dermatologie [CH Le Mans], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Recherche Agronomique (INRA)-Université de Bordeaux (UB)-École Nationale Supérieure d'Arts et Métiers (ENSAM), HESAM Université (HESAM)-HESAM Université (HESAM)-Institut Polytechnique de Bordeaux-Centre National de la Recherche Scientifique (CNRS), Infectiologie et Santé Publique (UMR ISP), Institut National de la Recherche Agronomique (INRA)-Université de Tours (UT), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Hôpital Saint-Jacques-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), and HESAM Université (HESAM)-HESAM Université (HESAM)-Institut Polytechnique de Bordeaux-Centre National de la Recherche Scientifique (CNRS)-Université de Bordeaux (UB)-Institut National de la Recherche Agronomique (INRA)
Subjects: Male, Skin Neoplasms, [SDV]Life Sciences [q-bio], Merkel cell polyomavirus, Kaplan-Meier Estimate, Gastroenterology, Serology, 030207 dermatology & venereal diseases, 0302 clinical medicine, Merkel cell carcinoma, Antigens, Viral, Tumor, ComputingMilieux_MISCELLANEOUS, Aged, 80 and over, education.field_of_study, T-Ag antibodies, biology, Middle Aged, Prognosis, 3. Good health, 030220 oncology & carcinogenesis, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, Antibody, Oncovirus, Adult, medicine.medical_specialty, Population, Enzyme-Linked Immunosorbent Assay, Dermatology, Risk Assessment, 03 medical and health sciences, Antigen, Internal medicine, Biomarkers, Tumor, Carcinoma, medicine, Humans, education, Aged, Polyomavirus Infections, VP1 antibodies, business.industry, medicine.disease, biology.organism_classification, Carcinoma, Merkel Cell, Tumor Virus Infections, Immunology, biology.protein, Capsid Proteins, Neoplasm Recurrence, Local, business
Abstract: International audience; Merkel cell polyomavirus (MCPyV) is the main etiological agent of Merkel cell carcinoma (MCC). Serum antibodies against the major MCPyV capsid protein (VP1) are detected in the general population, whereas antibodies against MCPyV oncoproteins (T-antigens) have been reported specifically in patients with MCC. The primary aim of this study was to assess whether detection of serum antibodies against MCPyV proteins at baseline was associated with disease outcome in patients with MCC. The secondary aim was to establish whether evolution of these antibodies during follow-up was associated with the course of the disease. Serum T-antigen and VP1 antibodies were assessed by ELISA using recombinant proteins in a cohort of 143 patients with MCC, including 84 patients with serum samples available at baseline. Low levels of VP1 antibodies at baseline (
Published: 2016
Full Text: View/download PDF

18. Development of monoclonal gammopathy under biotherapy in psoriasis: a French multicenter retrospective study

Author: Guillaume Chaby, Claire Bernier, Hervé Maillard, Annick Barbaud, Edouard Begon, Martine Avenel-Audran, Christine Pauwels, Phi Linh Nguyen-Thi, A.-L. Liegeon, François Maccari, E. Mahé, Ziad Reguiai, Céline Girard, Jean-Luc Schmutz, Eric Estève, A. Schoeffler, Claire Poreaux, Dominique Barthelme, L. Mery-Bossard, Nathalie Quiles-Tsimaratos, Service de Dermatologie et Allergologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Victor Dupouy, Centre Hospitalier René Dubos [Pontoise], Département de Dermatologie, Centre Hospitalier Régional d'Orléans (CHRO), Hôpital Saint-Joseph [Marseille], Département de dermatologie, CHU Angers, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Centre hospitalier F. Quesnay, CHI Poissy-Saint-Germain, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Service de dermatologie [CH Le Mans], Centre Hospitalier Le Mans (CH Le Mans), Centre hospitalier de Pau, Service de dermatologie [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de dermatologie [CHU d'Amiens-Picardie], CHU Amiens-Picardie, Département de Dermatologie [CHU de Reims], Centre Hospitalier Universitaire de Reims (CHU Reims), Service d'Epidémiologie et Evaluations Cliniques [CHRU Nancy] (Pôle S2R), Hôpital d'Instruction des Armées Begin, and Service de Santé des Armées
Subjects: Adult, Male, Pathology, medicine.medical_specialty, Paraproteinemias, Dermatology, 030207 dermatology & venereal diseases, 03 medical and health sciences, Biological Factors, 0302 clinical medicine, Psoriasis, medicine, Humans, Aged, Retrospective Studies, 030203 arthritis & rheumatology, business.industry, monoclonal gammopathy, Moderate to severe psoriasis, Retrospective cohort study, psoriasis, Middle Aged, medicine.disease, 3. Good health, Monoclonal gammopathy, biotherapy, Female, medicine.symptom, business, Monoclonal gammopathy of undetermined significance, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; BACKGROUND:Biotherapies or targeted therapies are fairly new treatments indicated for moderate to severe psoriasis. The side effects appear to be mainly infectious or cancerous. The role of biotherapies in the development of a pre-cancerous condition, monoclonal gammopathy of undetermined significance (MGUS), has recently been debated in the literature.OBJECTIVES:To evaluate the incidence of MGUS in psoriasis patients treated with biotherapy.MATERIALS AND METHODS:This study was a French multicenter retrospective study carried out through the French multicenter study group RESOPSO. Data on the results of serum protein electrophoreses performed before and within at least six months after the start of the biotherapy were collected. Demographic data, medical history, and psoriasis treatment history were specified.RESULTS:Four hundred and forty three patients were eligible for inclusion. Of these, three presented with monoclonal gammopathy for which the assessment was in favor of MGUS. The average treatment period was 19.7 months. Six patients presented with MGUS prior to the treatment. These patients' immunoglobulin levels remained stable, with an average remission of 24 months. Only psoriatic rheumatism appeared to be statistically linked to MGUS.CONCLUSION:The incidence and frequency of MGUS in psoriasis patients treated with biotherapy do not appear to increase relative to the general population.
Published: 2016
Full Text: View/download PDF

19. Prevalence of inherited ichthyosis in France: a study using capture-recapture method

Author: Sophie Henner, Isabelle Dreyfus, Pierre Vabres, Ludovic Martin, Cécile Chouquet, Sandrine Pascal, Jérôme A. Dupuis, Lauriane Rodriguez, Aude Maza, Christine Chiaverini, Juliette Mazereeuw-Hautier, Sébastien Barbarot, Khaled Ezzedine, Stéphanie Mallet, centre de référence des maladies rares de la peau, CHU Toulouse [Toulouse], Institut de Mathématiques de Toulouse UMR5219 (IMT), Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Centre de réréfence des maladies rares de la peau, CHU bordeaux, CHU Bordeaux [Bordeaux], Centre de référence de dermatologie pédiatrique, Centre Hospitalier Universitaire de Nice (CHU Nice), Centre de référence des maladies rares de la peau, CHU Toulouse, Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Département de dermatologie, CHU Angers, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Département de dermatologie, CHU Marseille, CHU Marseille, Centre de compétence des maladies rares de la peau, CHU Nantes, Centre hospitalier universitaire de Nantes (CHU Nantes), centre de référence des maladies rares de la peau, CHU Toulouse, Hôpital Larrey [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Centre de référence des maladies rares de la peau et des muqueuses d’origine génétique [CHU Toulouse] (CRMRP), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), and Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Male, medicine.medical_specialty, Congenital ichthyosiform erythroderma, Epidemiology, Hyperkeratosis, Mark and recapture, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, [MATH.MATH-ST]Mathematics [math]/Statistics [math.ST], Congenital ichthyosis, medicine, Prevalence, Humans, Genetics(clinical), Pharmacology (medical), Genodermatosis, Genetics (clinical), Genetics, Medicine(all), Ichthyosis, business.industry, Research, General Medicine, [STAT.TH]Statistics [stat]/Statistics Theory [stat.TH], Lamellar ichthyosis, medicine.disease, Inherited ichthyosis, Dermatology, 3. Good health, Female, France, business, 030217 neurology & neurosurgery, Capture-recapture method
Abstract: International audience; BACKGROUND:Inherited ichthyoses represent a group of rare skin disorders characterized by scaling, hyperkeratosis and inconstant erythema, involving most of the tegument. Epidemiology remains poorly described. This study aims to evaluate the prevalence of inherited ichthyosis (excluding very mild forms) and its different clinical forms in France.METHODS:Capture - recapture method was used for this study. According to statistical requirements, 3 different lists (reference/competence centres, French association of patients with ichthyosis and internet network) were used to record such patients. The study was conducted in 5 areas during a closed period.RESULTS:The prevalence was estimated at 13.3 per million people (/M) (CI95%, [10.9 - 17.6]). With regard to autosomal recessive congenital ichthyosis, the prevalence was estimated at 7/M (CI 95% [5.7 - 9.2]), with a prevalence of lamellar ichthyosis and congenital ichthyosiform erythroderma of 4.5/M (CI 95% [3.7 - 5.9]) and 1.9/M (CI 95% [1.6 - 2.6]), respectively. Prevalence of keratinopathic forms was estimated at 1.1/M (CI 95% [0.9 - 1.5]). Prevalence of syndromic forms (all clinical forms together) was estimated at 1.9/M (CI 95% [1.6 - 2.6]).CONCLUSIONS:Our results constitute a crucial basis to properly size the necessary health measures that are required to improve patient care and design further clinical studies.
Published: 2014
Full Text: View/download PDF

20. Immunomodulatory and/or immunosuppressive drugs should not be stopped prior to skin tests for the assessment of drug allergy

Author: S El Mesbahi, Delphine Staumont-Sallé, J Grosjean, Damien Lannoy, C Nassar, Florence Tetart, B. Tedbirt, F. Dezoteux, Sophie Gautier, Département de Dermatologie [CHRU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Dermatologie [Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Laboratoire d'Informatique Médicale et Ingénierie des Connaissances en e-Santé (LIMICS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Sorbonne Paris Nord, Département d'Informatique Médicale (D2IM), Centre Régional de PharmacoVigilance Nord-Pas-de-Calais [CHU Lille] (CRPV), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Faculté de Médecine Henri Warembourg - Université de Lille, CHU Lille, Institut de Pharmacie, Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), and Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)
Subjects: Drug, medicine.medical_specialty, media_common.quotation_subject, Drug allergy, Dermatology, Chronic inflammatory disease, Drug Hypersensitivity, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, [SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication, medicine, Humans, In patient, Skin Tests, media_common, business.industry, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Skin test, medicine.disease, 3. Good health, Skin reaction, 030228 respiratory system, Underlying disease, business, Immunosuppressive Agents
Abstract: International audience; The use of immunomodulatory and/or immunosuppressive therapy (IT) is increasingly common in the management of chronic inflammatory disease. Skin reactions to any drug (IT or not) are not rare in these patients, justifying allergological investigations. The influence of IT on allergological tests for drugs is not clearly described. IT cannot be interrupted due to the underlying disease. The data assessing the benefit and the safety of allergological test for drug allergy in patients under IT are missing.
Published: 2022
Full Text: View/download PDF

21. First use of the Adolescent Depression Rating Scale (ADRS) in the management of young people with severe acne treated with isotretinoin: a pilot study of an active monitoring of depressive disorders by dermatologists

Author: Olivier Chosidow, J. Micallef, L Hefez, Elisabeth Jouve, Brigitte Dréno, Bruno Falissard, A Revah-Levy, Grand Hôpital de l'Est Francilien (GHEF), Institut de Neurosciences des Systèmes (INS), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Victor Dupouy, Equipe 2 : ECSTRA - Epidémiologie Clinique, STatistique, pour la Recherche en Santé (CRESS - U1153), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Centre hospitalier universitaire de Nantes (CHU Nantes), Département de dermatologie, hôpital Henri Mondor, CHU Henri Mondor [Créteil], Dynamic Microbiology - EA 7380 (DYNAMIC), École nationale vétérinaire - Alfort (ENVA)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Université Paris-Est (UPE)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), and CHU Henri Mondor
Subjects: Pediatrics, medicine.medical_specialty, Adolescent, MESH: Depressive Disorder, Pilot Projects, Dermatology, Rating scale, MESH: Isotretinoin, Acne Vulgaris, Humans, Medicine, Prospective Studies, Isotretinoin, skin and connective tissue diseases, Prospective cohort study, Acne, Depression (differential diagnoses), ComputingMilieux_MISCELLANEOUS, MESH: Acne Vulgaris, Depressive Disorder, Depression, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, Confounding, medicine.disease, Mental health, MESH: Dermatologists, Mood, Dermatologic Agents, business, Dermatologists, medicine.drug
Abstract: Summary Background During isotretinoin treatment, special attention is required to detect any symptom or change in the mental health of patients. The monitoring is complex for adolescents because of confounding factors such as mood changes associated with adolescence and puberty and the higher psychosocial impairment due to the acne itself. Aim To determine the utility of the Adolescent Depression Rating Scale (ADRS) for monitoring symptoms in adolescents before and during isotretinoin treatment in dermatology real-life practice. Methods This was a national, multicentre prospective study that enrolled a random sample of dermatologists treating adolescents. An algorithm including ADRS score and its changes between consecutive visits was used. At each visit, dermatologists rated their satisfaction with ADRS and its ease of use, while patients rated the acceptability of the ADRS. Results In total, 70 dermatologists used the algorithm for 1227 visits of 283 adolescents receiving isotretinoin. Of these 70 dermatologists, 80.8% were satisfied/very satisfied with the ADRS, 82.7% considered the use of the ADRS in clinical practice to be easy/very easy and 75% considered that the ADRS enabled them to discuss more easily the risk of depression with their patients. For the patients, acceptability of the ADRS was considered good by 93.8%. Conclusions The implementation of the ADRS could be valuable in dermatology practice, optimizing the monitoring of patients and the good use of isotretinoin.
Published: 2022
Full Text: View/download PDF

22. TRASS: a global approach to assess the severity of truncal acne

Author: N. Auffret, J.M. Nguyen, M.‐T. Leccia, J.P. Claudel, B. Dréno, Private Practice [Paris], Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers (CRCI2NA ), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Département de dermatologie, allergologie et photobiologie [Hôpital Michallon du CHU Grenoble Alpes], Centre Hospitalier Universitaire [Grenoble] (CHU)-Hôpital Michallon, Private Practice [Tours], Immunology and New Concepts in ImmunoTherapy (INCIT), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), CIC biothérapies CBT 0503 [Nantes], Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Département de Dermato-Cancerologie [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), and Pecqueret, Valérie
Subjects: Male, truncal acne, trunk, [SDV]Life Sciences [q-bio], Torso, Dermatology, Administration, Cutaneous, Severity of Illness Index, scale, [SDV] Life Sciences [q-bio], Cicatrix, Infectious Diseases, scoring tool, Acne Vulgaris, Quality of Life, Humans, Female, acne severity, acne
Abstract: International audience; Introduction: Only a small amount of published data regarding truncal acne is available and no proper tool to assess its severity exists.Aim: to provide dermatologists with an easy-to-use tool to assess truncal acne (TRASS, truncal acne severity scale) using a global approach.Methods: A scoring tool that assesses the severity of acne (based on GEA and ECLA scales) on the trunk using a global approach was built, including three subscores: family history, clinical signs and quality of life (QoL). In order to test TRASS, the experts used photos of 47 patients attending their clinics with truncal acne. The ROP (Regression OPtimized) model was applied to assess the diagnosis performance of TRASS and to identify items contributing to the classification of the patients. Internal testing was made to demonstrate the robustness of the model. Correlation analyses between the different items were performed to evaluate the interaction between the different items and their impact on the severity grading of truncal acne.Results: Patients with the most severe acne were identified by TRASS. The error level was 6.6% after internal validation and 10.4% when using the median value or the centile 75th (6.6% and 10.4%). Correlation was significant between systemic treatment and scars (p=0.0025) and nodules (p=0.01988) and between location and QoL (p=0.0095).Conclusion: TRASS is the first global, patient-centred approach to evaluate truncal acne by scoring the importance of each factor independently from its clinical severity. TRASS may allow the practitioner to choose and validate the most suitable therapy together with the patient in order to treat his or her truncal acne successfully and to limit treatment failure.
Published: 2021
Full Text: View/download PDF

23. Éruptions eczématiformes chroniques du sujet âgé : quelle imputabilité médicamenteuse ?

Author: Marie Jachiet, Claire Boulard, Delphine Staumont-Sallé, Catherine Droitcourt, Robin Guelimi, Florence Tetart, Julie Bouteiller, Haudrey Assier, Brigitte Milpied, Emilie Brenaut, Julien Grosjean, Manuelle Viguier, Marie-Christine Ferrier Le Bouedec, Pascal Joly, Audrey Nosbaum, Pauline Bouschon, Nadia Raison-Peyron, Corina Bara, A. Valois, J. Delaunay, Justine Pasteur, F. Dezoteux, Saskia Oro, C. Morice, Service de Dermatologie [Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU), CHU de Rouen, Département d’informatique et d’information médicales, Laboratoire d'Informatique Médicale et Ingénierie des Connaissances en e-Santé (LIMICS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Sorbonne Paris Nord, Département de dermatologie [CHU Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de Dermatologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de dermatologie [CH Le Mans], Centre Hospitalier Le Mans (CH Le Mans), Service d'allergologie et immunologie clinique, Centre hospitalier Lyon Sud, Hospices civils de Lyon, Service de Dermatologie, Centre Hospitalier Sud, Hospices Civils, Lyon, Service de dermatologie [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Dermatology Department [Créteil], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Service de dermatologie, hôpital d'instruction des armées Sainte-Anne, Toulon, Service de dermatologie (CHU de Reims), Centre Hospitalier Universitaire de Reims (CHU Reims), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de dermatologie, hôpital Jacques-Monod, Le Havre, Service de dermatologie (Dermato - BREST), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Service de Dermatologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Dermatologie [Rennes] = Dermatology [Rennes], CHU Pontchaillou [Rennes], Service de Dermatologie et Oncologie Cutanée [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Service de Dermatologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de pneumologie, allergologie, mucoviscidose pédiatrique [Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Hôpital Charles Nicolle [Rouen]-CHU Rouen, CHU Caen, and Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN)
Subjects: Médicaments, Ocean Engineering, Eczéma, MESH: Inhibiteurs des canaux calciques, 3. Good health, MESH: Préparations pharmaceutiques, 030207 dermatology & venereal diseases, 03 medical and health sciences, MESH: Eczéma, 0302 clinical medicine, [SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication, Inhibiteurs calciques, 030220 oncology & carcinogenesis, Personne âgée, Safety, Risk, Reliability and Quality, MESH: Sujet âgé, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract: Introduction Le role des medicaments dans la survenue d’eruptions eczematiformes du sujet âge (EESA) a ete suggere dans une etude cas-temoin francaise montrant une frequence de prise des inhibiteurs calciques de 26 % chez les patients ayant une EESA (OR de 2,5 par rapport aux temoins sans eczema). Ces resultats ont ensuite ete confirmes par une etude retrospective americaine. Des cas isoles d’EESA ont depuis ete rapportes avec le clopidogrel, les IEC, les ARAII et les diuretiques. Notre etude initiale ayant ete realisee il y a 15 ans, nous en avons realise une nouvelle pour reevaluer l’association entre les prises medicamenteuses et les EESA. Materiel et methodes Cette etude retrospective a ete conduite dans 16 centres du GREAT, FISARD ou DAG de 2018 a 2020. Nous avons compare la frequence des 10 classes medicamenteuses les plus prescrites entre la population etudiee (patients de plus de 65 ans developpant un eczema chronique sans cause identifiee) et la population generale de reference du meme âge dont les donnees ont ete obtenues grâce a l’Echantillon Generaliste des Beneficiaires (EGB) issu de la base informatique de la Securite Sociale, apres standardisation indirecte sur le sexe et l’âge. Tous les patients inclus avaient des lesions eczematiformes etendues (plus de 20 % de la surface corporelle), depuis plus de 3 mois. Une biopsie cutanee evocatrice d’eczema devait avoir ete realisee ainsi qu’une immunofluorescence directe negative ou des anticorps BPAG 1 et 2 negatifs afin d’eliminer une pemphigoide au stade pre-bulleux. Les patients n’avaient pas d’antecedent de dermatite atopique dans l’enfance. Resultats Cent quatre vingt cinq patients (120 H et 65 F) d’âge moyen 79,5 ± 7,5 ans ont ete inclus. L’hypertension arterielle representait la comorbidite la plus frequente (69,7 % des patients). Les patients prenaient en moyenne 5,0 ± 3,2 medicaments. Les medicaments les plus frequemment prescrits etaient les inhibiteurs calciques (39,5 %), les statines (36,8 %), les antiagregants plaquettaires (31,9 %), les betabloquants (30,8 %), les ARA2 (29,2 %), les diuretiques thiazidiques (23,8 %), les IEC (22,7 %), les IPP (21,6 %), les diuretiques de l’anse (17,8 %) et les benzodiazepines (15,1 %). Un ou plusieurs medicaments etaient arretes chez 60 (32,4 %) patients. Parmi eux, 31 (51,7 %) ne presentaient plus de lesion a 6 mois. L’analyse comparative par rapport a l’EGB est en cours. Discussion Les caracteristiques des patients concordent avec celles observees dans notre etude precedente, en particulier la predominance masculine et la polymedication. La frequence de prise des inhibiteurs calciques (39,5 %) est encore plus elevee (× 1,5) que dans notre etude initiale confirmant le tres fort risque lie a cette classe medicamenteuse. La comparaison avec les donnees de l’EGB (analyse en cours avec resultats prevus prochainement) permettra peut-etre de mettre en evidence une association avec d’autres classes medicamenteuses.
Published: 2021
Full Text: View/download PDF

24. La complexité du parcours de soin du patient atteint de dermatite atopique modérée à sévère en quête d’un nouveau traitement : données d’une étude anthropologique qualitative

Author: Laurent Misery, Margaux Noël, Sébastien Barbarot, Stéphane Héas, Fabienne Martin Juchat, Judith Nicogossian, Anthropologie bio-culturelle, Droit, Ethique et Santé (ADES), Aix Marseille Université (AMU)-EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique (CNRS), Violences, Innovations, Politiques, Socialisations et Sports (VIPS2), Le Mans Université (UM)-École normale supérieure - Rennes (ENS Rennes)-Université de Rennes 2 (UR2), Département de Dermatologie [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Physiopathologie des Adaptations Nutritionnelles (PhAN), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Laboratoire sur les interactions Epithéliums Neurones (LIEN), Université de Brest (UBO), Pfizer, and Université Grenoble Alpes (UGA)
Subjects: Dermatite atopique, [SDV]Life Sciences [q-bio], Insuffisance thérapeutique, Ocean Engineering, Safety, Risk, Reliability and Quality, Anthropologie
Abstract: Introduction Des mecanismes de l’insuffisance therapeutique du point de vue du patient ont ete decrits par l’etude VECUDA, menee par des anthropologues en cooperation avec des dermatologues. Celle-ci avait pour but de rechercher les mecanismes de satisfaction et d’insatisfaction chez les patients atteints de dermatite atopique (DA) moderee a severe en se focalisant sur le recit des affects marquant leur parcours de soin. Au cours de cette etude exploratoire, a emerge, sans que cela soit attendu, une figure de patients qui voyait un sentiment d’election en l’acces a un traitement qui etait la premiere biotherapie dans le traitement de la DA. Nous nous interessons ici au vecu du parcours de soin par ces patients. Materiel et methodes L’etude qualitative VECUDA a concerne 24 patients. Au cours d’entretiens collectifs, animes grâce a des outils de creativite, les recits des patients en lien a leur maladie et sa prise en charge ont ete associes a des affects (ou ressentis). L’etude fut menee en deux phases: – une pre-etude (4 patients) a permis la construction de la methode et l’identification de pistes de recherches et la proposition d’outils concrets, – l’etude elle-meme (20 patients) a permis d’approfondir et d’affiner les apports de la pre-etude. Les patients ont ete recrutes librement sur des criteres d’inclusion en lien a leurs aptitudes a communiquer sur leurs emotions et la diversite de leurs profils. Resultats Une minorite des patients interroges (2 patients sur 4 de la pre-etude et 6 patients sur 20 de l’etude) ont decrit les difficultes rencontrees au cours de leur parcours de soin et plus particulierement dans l’acces a un nouveau traitement, ici la premiere biotherapie dans la DA. Ces patients ressentaient un manque d’information sur la maladie et sur les nouveaux traitements disponibles. La strategie de prescription du traitement, soulevant la question de l’eligibilite, etait quant a elle souvent incomprise. Discussion L’acces parfois rendu difficile aux nouveaux traitements peut etre percu par les patients comme inegalitaire et aleatoire. Les informations limitees dont disposent les patients conditionnent egalement ce ressenti. La complexite du parcours peut expliquer le sentiment d’election evoque par les patients lorsqu’ils accedent au traitement. Le parcours de soin des patients en quete d’un nouveau traitement est vecu comme un veritable parcours initiatique. Les patients conferent au traitement, au-dela de sa fonction therapeutique, une valeur symbolique. La comprehension de la perception du parcours de soin par ces patients pourrait aider les praticiens a apprehender les besoins et attentes de ceux-ci, dans une perspective d’amelioration de la qualite de la relation medecin – malade et la satisfaction therapeutique.
Published: 2021
Full Text: View/download PDF

25. Immunomodulatory or/and immunosuppressive drugs should not avoid skin test for the assessment of drug allergy

Author: Dezoteux, F., El Mesbahi, S., Tedbirt, B., Grosjean, J., Gautier, S., Lannoy, D., Nassar, C., Tétart, F., Staumont‐Sallé, D., Département de Dermatologie [CHRU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Dermatologie [Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU), CHU de Rouen, Département d’informatique et d’information médicales, Laboratoire d'Informatique Médicale et Ingénierie des Connaissances en e-Santé (LIMICS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Sorbonne Paris Nord, Centre Régional de PharmacoVigilance Nord-Pas-de-Calais [CHU Lille] (CRPV), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université Lille 2 - Faculté de Médecine, CHU Lille, Institut de Pharmacie, Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), and Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)
Subjects: [SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology
Abstract: International audience; The use of immunomodulatory and/or immunosuppressive therapy (IT) is increasingly common in the management of chronic inflammatory disease. Skin reactions to any drug (IT or not) are not rare in these patients, justifying allergological investigations. The influence of IT on allergological tests for drugs is not clearly described. IT cannot be interrupted due to the underlying disease. The data assessing the benefit and the safety of allergological test for drug allergy in patients under IT are missing.
Published: 2021
Full Text: View/download PDF

26. PD-L1 in circulating exosomes of Merkel cell carcinoma

Author: Anaïs Zanella, Valentin Vautrot, François Aubin, Laure Avoscan, Mahtab Samimi, Carmen Garrido, Jessica Gobbo, Charlée Nardin, Chanteloup, Nathalie Katy, Département de dermatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Laboratoire d'Excellence : Lipoprotéines et Santé : prévention et Traitement des maladies Inflammatoires et du Cancer (LabEx LipSTIC), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Gustave Roussy (IGR)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM)-Fédération Francophone de la Cancérologie Digestive, FFCD-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Institut Agro Dijon, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Université de Montpellier (UM), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Agroécologie [Dijon], Université de Bourgogne (UB)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Institut Agro Dijon, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Service de dermatologie (CHRU de Tours), Infectiologie et Santé Publique (UMR ISP), Université de Tours (UT)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre d'Investigation Clinique 1432 (Dijon) - Module Plurithématique : Périnatalité Cancérologie Handicap et Ophtalmologie (CIC-P803), Université de Bourgogne (UB)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, and bourse of CARADERM 2020
Subjects: PD-L1, Skin Neoplasms, [SDV]Life Sciences [q-bio], food and beverages, [SDV.CAN]Life Sciences [q-bio]/Cancer, Dermatology, [SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology, Exosomes, Biochemistry, B7-H1 Antigen, [SDV] Life Sciences [q-bio], Carcinoma, Merkel Cell, Cohort Studies, anti-PD L1, Merkel cell carcinoma, [SDV.CAN] Life Sciences [q-bio]/Cancer, biomarker, Humans, avelumab, immunotherapy, Prospective Studies, Molecular Biology, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract: International audience; Exosomes, as potential circulated biomarkers, have recently become a topic of interest in the field of oncology. Immune checkpoint molecule PD-L1 has recently been detected in circulating exosomes from cancer patients. The purpose of this work was to evaluate PD-L1 levels in circulating exosomes (Exo-PD-L1) isolated from patients' plasma suffering from Merkel cell carcinoma (MCC). We conducted a prospective bicentric cohort study. PD-L1 was analysed in circulating exosomes from plasma samples of patients suffering from MCC stage I to IV (according to the AJCC 8). Exosomes from 34 patients corresponding to 66 samples were analysed. PD-L1 was identified in circulating exosomes of MCC patients. Exo-PD-L1 levels of MCC patients were similar to healthy donors and lower than other cancers such as melanoma. Exo-PD-L1 levels tended to be higher in MCC patients with distant metastases. Furthermore, Exo-PD-L1 levels did not significantly vary over the course of the disease whatever the disease course or the response to treatment. This study assessed the presence of PD-L1 in circulating exosomes of MCC patients. The low levels of Exo-PD-L1 and small changes over the course of the disease may be due to the metastatic dissemination of MCC, which is mainly through the skin and lymph nodes rather than blood. PD-L1 was identified in circulating exosomes of MCC patients and tends to be higher in advanced disease. This preliminary study is a proof of concept of PD-L1 detection in circulating exosomes of MCC patients.
Published: 2021
Full Text: View/download PDF

27. Cutaneous granulomas with primary immunodeficiency in children: a report of 17 new patients and a review of the literature

Author: Capucine Picard, D Moshous, Nizar Mahlaoui, A Fischer, C Bodemer, Sylvie Fraitag, S Blanche, Philippe Pérot, Ludovic Martin, B Neven, Stéphanie Leclerc-Mercier, Isabelle Pellier, Marc Eloit, Service de pathologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de référence national des Maladies Génétiques à Expression Cutanée (MAGEC), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Service de dermatologie [CHU Necker], Service d'immuno-hématologie pédiatrique [CHU Necker], Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Référence Déficits Immunitaires Héréditaires (CEREDIH), Département de dermatologie [CHU Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), PRES Université Nantes Angers Le Mans (UNAM), Centre d'étude des Déficits Immunitaires, Chaire Médecine expérimentale (A. Fischer), Collège de France (CdF (institution)), Découverte de Pathogènes - Pathogen Discovery, Biologie des Infections - Biology of Infection, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), École nationale vétérinaire d'Alfort (ENVA), Centre de référence national des Maladies Génétiques à Expression Cutanée - National Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Collège de France - Chaire Médecine expérimentale (A. Fischer), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), and École nationale vétérinaire - Alfort (ENVA)
Subjects: Heart Defects, Congenital, Male, 0301 basic medicine, medicine.medical_specialty, Primary Immunodeficiency Diseases, [SDV]Life Sciences [q-bio], Dermatology, medicine.disease_cause, Skin Diseases, Ataxia Telangiectasia, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Cutaneous granuloma, hemic and lymphatic diseases, Skin Ulcer, Biopsy, medicine, Humans, Abnormalities, Multiple, Child, Immunodeficiency, Uterine Diseases, Granuloma, medicine.diagnostic_test, business.industry, Infant, Hydrocolpos, Rubella virus, medicine.disease, Hypoplasia, Pathophysiology, 3. Good health, Polydactyly, 030104 developmental biology, Infectious Diseases, Child, Preschool, Concomitant, Primary immunodeficiency, Female, Severe Combined Immunodeficiency, business
Abstract: International audience; BACKGROUND: Paediatric cutaneous granuloma with primary immunodeficiency (PID) is a rare condition. The physiopathology is unclear, and treatment is challenging. We report on 17 paediatric cases and review the literature.OBJECTIVES: To make dermatologists and dermatopathologists aware of the diagnostic value of skin granulomas in paediatric PID.METHODS: We collected data on 17 patients with cutaneous granulomas and PID registered with us and also reviewed 33 cases from the literature.RESULTS: Cutaneous granuloma was the presenting feature of the PID in 15 of the 50 collated cases. The lesions presented as red-brownish nodules and infiltrated ulcerative plaques, predominantly on the face and limbs. Scleroderma-like infiltration on a single limb was observed in 10% of the cases. The associated PID was ataxia-telangiectasia (52%), combined immunodeficiency (24%), cartilage-hair hypoplasia (6%) and other subtypes (18%). The granulomas were mostly sarcoidal, tuberculoid, palisaded or undefined subtypes. In some patients, several different histopathologic granulomatous patterns were found in the same biopsy. Some granulomas were associated with the presence of a vaccine strain of rubella virus.CONCLUSION: Cutaneous granulomas associated with a PID have a variable clinical presentation. A PID can be suspected when crusty, brownish lesions are found on the face or limbs. The concomitant presence of several histological subtypes in a single patient is suggestive of a PID.
Published: 2019
Full Text: View/download PDF

28. Immunoblot for the Diagnosis of Cutaneous Leishmaniasis in French Guiana

Author: Romain Blaizot, Coralie L'Ollivier, Stéphane Simon, Stéphane Ranque, Antoine Adenis, Charles Mary, Estelle Menu, Denis Blanchet, Magalie Demar, Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche Biomédicale des Armées (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), Département de dermatologie [CH andré-Rosemont, Cayenne], Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Ecosystemes Amazoniens et Pathologie Tropicale (EPat), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Guyane (UG), Centre d'investigation clinique Antilles-Guyane (CIC - Antilles Guyane), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU de la Martinique [Fort de France]-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Université de Guyane (UG), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de la Martinique [Fort de France]-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Vecteurs - Infections tropicales et méditerranéennes [VITROME], Biome Tropical et Immuno-Pathophysiologie = Tropical Biome and ImmunoPhysiopathology [Lille] [TBIP], Centre d'investigation clinique Antilles-Guyane [CIC - Antilles Guyane], Université de Guyane [UG], Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), and COMBE, Isabelle
Subjects: Male, Endemic Diseases, Antibodies, Protozoan, Serology, Tertiary Care Centers, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Leishmania, 0303 health sciences, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, biology, Dermatology department, Articles, Middle Aged, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, French Guiana, 3. Good health, Infectious Diseases, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Female, Antibody, [SDV.MP.PAR] Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, Adult, medicine.medical_specialty, Adolescent, Immunoblotting, Leishmaniasis, Cutaneous, Antigens, Protozoan, Sensitivity and Specificity, Young Adult, 03 medical and health sciences, Antigen, Cutaneous leishmaniasis, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Virology, medicine, Humans, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, Retrospective Studies, 030304 developmental biology, Autoimmune disease, 030306 microbiology, business.industry, Odds ratio, medicine.disease, Dermatology, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Immunoglobulin G, biology.protein, Parasitology, [SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, business
Abstract: Cutaneous leishmaniasis (CL) is firmly established in South America. We aimed to assess the detection of IgG antibodies against 14 and/or 16 kDa antigens by immunoblot (IB) for CL serological diagnosis in French Guiana, an area where many endemic pathogens could interfere with it. This study was performed retrospectively on sera from 141 patients at the Cayenne tertiary hospital: 30 were patients with confirmed CL, 71 were diagnosed with various other endemic pathogens, 11 were diagnosed with an autoimmune disease, and 29 controls had no history of CL. Antibodies bound to the 14 and/or 16 kDa antigens in 27 of the 30 CL patients’ sera and in 39 of the 111 non-CL patients’ sera (26 from the infectious diseases group, four from the autoimmune diseases group, and nine from the dermatology department). The method tested showed a high sensitivity (90%) and a low specificity (66%), and a diagnosis odds ratio of 17.5 (95% CI [4.6–78.0]). This IB may be helpful to exclude the diagnosis of CL, prompting physicians to look for another diagnosis in the case of a negative IB.
Published: 2021
Full Text: View/download PDF

29. Out‐of‐pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross‐sectional, non‐comparative, multicentre study

Author: Richard, M.‐a., Paul, C., de Pouvourville, G., Jullien, D., Mahe, E., Bachelez, H., Seneschal, J., Misery, L., Aubert, R., Reguiai, Z., Shourick, J., Taieb, C., Joly, P., Ezzedine, K., Essec Business School, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Victor Dupouy, Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Bordeaux (UB), Laboratoire sur les interactions Epithéliums Neurones (LIEN), Université de Brest (UBO), Département de Dermatologie [CHU de Reims], Centre Hospitalier Universitaire de Reims (CHU Reims), CHU Toulouse [Toulouse], European Market Maintenance Assessment [Fontenay-sous-Bois] (EMMA ), Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de dermatologie [Mondor], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
Subjects: vitiligo, Mesures adjuvantes, MESH: Interferon-gamma, Associated measures, MESH: Long-Term Care, MESH: Skin, interferon-γ, MESH: Melanocytes, MESH: Physicians, MESH: Surveys and Questionnaires, skin and connective tissue diseases, Prescriber, Systemic glucocorticoid therapy, MESH: Humans, MESH: Long Term Adverse Effects, MESH: Middle Aged, integumentary system, Corticothérapies systémiques, pathogenesis, MESH: Polypharmacy, cytotoxic CD8+ T cells, targeted therapies, MESH: Keratinocytes, MESH: Male, Prescripteur, MESH: Practice Patterns, Physicians', MESH: Specialization, MESH: Vitiligo, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract: International audience; Vitiligo is the most common depigmenting disorder affecting 0.1%-2% of the population worldwide. The characteristic white patches result from the selective loss of melanocytes. Sustained recent efforts have resulted in a detailed understanding of the genetic architecture of vitiligo. About 80% of vitiligo risk is attributable to genetic factors; and the rest (20%) is attributable to the environment. Over the past decade, substantial progress has been made in our understanding of the pathogenesis of vitiligo which is now clearly classified as an autoimmune disease. Melanocytes from patients with vitiligo are more susceptible to oxidative stress which begets the release of exosomes and inflammatory cytokines that will lead to activation of the innate immune response and subsequently to adaptive immune response through activation of autoreactive cytotoxic CD8+ T cells. These produce interferon-γ (IFN-γ) which promotes disease progression through IFN-γ-induced chemokine secretion from surrounding keratinocytes to further recruit T cells to the skin through a positive feedback loop. CD8 tissue-resident memory T cells are in turn responsible for long-term maintenance and potential relapse of vitiligo in human patients through cytokine-mediated recruitment of T cells from the circulation. This review summarizes the current knowledge on vitiligo and attempt to give an overview of the future in vitiligo treatment.
Published: 2021
Full Text: View/download PDF

30. Topical sirolimus 1% for benign lymphangiomatous papules after radiotherapy for endometrial and breast cancers: a report of three cases

Author: Sophie Leducq, Annabel Maruani, Matthias Tallegas, C. Poiraud, J. Zaragoza, R. Gabeff, Service de dermatologie, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN)-Université de Nantes (UN), Département de Dermatologie, Centre Hospitalier Régional d'Orléans (CHRO), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), and Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques
Subjects: medicine.medical_specialty, Skin Neoplasms, medicine.medical_treatment, [SDV]Life Sciences [q-bio], MEDLINE, Breast Neoplasms, Dermatology, Administration, Cutaneous, medicine, Humans, Thoracic Wall, ComputingMilieux_MISCELLANEOUS, Aged, Sirolimus, Antibiotics, Antineoplastic, Lymphangioma, Radiotherapy, Vulvar Neoplasms, business.industry, Middle Aged, Endometrial Neoplasms, 3. Good health, Radiation therapy, Female, Topical Sirolimus, business
Abstract: International audience
Published: 2021
Full Text: View/download PDF

31. Facteurs prédictifs de réponse au méthotrexate dans la dermatite atopique de l’adulte

Author: Audrey Nosbaum, J. Delaunay, Jean-François Nicolas, Aurélie Du Thanh, Angèle Soria, Julien Seneschal, Louise Jaulent, Pauline Pralong, Muriel Rabilloud, F. Hacard, Sébastien Barbarot, Coline Jaulent, Catherine Goujon, Florence Tetart, Clementine Toussaint, Nadia Raison-Peyron, Delphine Staumont-Sallé, Service d'allergologie et immunologie clinique, Centre hospitalier Lyon Sud, Hospices civils de Lyon, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Brest (UBO), Centre de Recherche sur l'Education, les apprentissages et la didactique (CREAD EA 3875), Université de Brest (UBO)-Université de Rennes 2 (UR2)-Institut Brestois des Sciences de l'Homme et de la Société (IBSHS), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Department of Allergology and Clinical Immunology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, parent, Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Saint-André, University of Saint Andrews, Physiopathologie des Adaptations Nutritionnelles (PhAN), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Département de dermatologie [CHU Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Pathogenesis and Control of Chronic and Emerging Infections (PCCEI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université des Antilles (UA)-Etablissement français du don du sang [Montpellier], Centre Hospitalier Universitaire [Grenoble] (CHU), Service de Dermatologie [Montpellier], Service de Dermatologie [Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Service de pneumologie, allergologie, mucoviscidose pédiatrique [Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Dermatite atopique, [SDV]Life Sciences [q-bio], Éosinophilie, Ocean Engineering, Méthotrexate, Tabagisme, Safety, Risk, Reliability and Quality
Abstract: International audience
Published: 2021
Full Text: View/download PDF

32. Les engelures apparues pendant le confinement sont associées à une exposition au SARS-CoV-2

Author: Valérie Gissot, Vincent Thibault, Alexis Toubel, Hélène Aubert, Christopher Heslan, L. Martin, Estel Chambrelan, Yannick Le Corre, Emilie Brenaut, Mahtab Samimi, Florence Poizeau, Alain Dupuy, Emmanuel Oger, C. Laurent, Laurent Misery, Sébastien Barbarot, Catherine Droitcourt, Pierre Tattevin, CHU Pontchaillou [Rennes], Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Physiopathologie des Adaptations Nutritionnelles (PhAN), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Service de dermatologie (Dermato - BREST), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Département de Dermatologie [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Service de Dermatologie [Rennes] = Dermatology [Rennes], Centre d’Investigation Clinique [Tours] CIC 1415 (CIC ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité Mixte de Recherche sur les Herbivores - UMR 1213 (UMRH), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire sur les interactions Epithéliums Neurones (LIEN), Université de Brest (UBO), Pfizer, ARN régulateurs bactériens et médecine (BRM), and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
Subjects: SARS-CoV-2, P191, [SDV]Life Sciences [q-bio], Manifestations acrales, COVID-19, Ocean Engineering, Safety, Risk, Reliability and Quality, Engelures
Abstract: Introduction De nombreux cas d’engelures ont ete rapportes depuis le debut de la pandemie de Covid-19. Cependant, la RT-PCR et la serologie ne mettaient pas en evidence d’infection a SARS-CoV-2 chez la majorite des patients. L’hypothese d’une reponse interferon-mediee au SARS-CoV-2, permettant une clairance rapide du virus qui ne pourrait alors pas activer l’immunite humorale, a ete soulevee et pourrait expliquer la seronegativite. Notre objectif etait de rechercher une association entre les engelures survenues pendant le premier confinement en France et l’exposition au SARS-CoV-2 au sein des foyers. Materiel et methodes Dans cette etude cas-temoins multicentrique, les cas etaient les 102 individus adresses entre mars et mai 2020 aux CHU de Rennes, Nantes, Angers, Tours, et Brest pour des engelures. Les temoins etaient recrutes a partir des fichiers de volontaires sains tenus par ces hopitaux. Tous les membres de ces foyers etaient inclus, constituant ainsi 77 foyers cas (262 individus) et 74 foyers temoins (230 individus). L’exposition des foyers au SARS-CoV-2 lors du premier confinement etait categorisee en 3 niveaux : faible, intermediaire ou eleve, a partir d’un algorithme prenant en compte les symptomes, les contacts a risque et les activites hors du foyer des individus de chaque foyer. Une serologie SARS-CoV-2 etait proposee a tous les individus. Resultats Apres ajustement sur l’âge, l’association entre engelures et exposition au SARS-CoV-2 au sein des foyers de confinement etait estimee a 3,3, intervalle de confiance a 95 % (1,4–7,3), pour un niveau d’exposition intermediaire, et a 6,9 (2,5–19,5) pour un niveau d’exposition eleve au SARS-CoV-2. Parmi les 57 foyers cas ayant eu une serologie, 6 (11 %) avaient developpe des anticorps anti- SARS-CoV-2, alors que tous les foyers temoins testes etaient seronegatifs (n = 50). Discussion Cette etude cas-temoin demontre l’association entre engelures et exposition des foyers au SARS-CoV-2 durant le premier confinement. Notre critere de jugement etant declaratif, un biais de memorisation etait possible. Cependant, meme si 20 % des patients etaient classes exposes au SARS-CoV-2 par erreur, la mesure d’association resterait significative.
Published: 2021
Full Text: View/download PDF

33. Validation of Swab Sampling and SYBR Green-Based Real-Time PCR for the Diagnosis of Cutaneous Leishmaniasis in French Guiana

Author: D. Blanchet, Marine Ginouves, P. Couppié, Ghislaine Prévot, M. Demar, Cécile Nabet, Romain Blaizot, Christophe Ravel, Stéphane Simon, Département de dermatologie [CH andré-Rosemont, Cayenne], Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Biome Tropical et Immuno-Pathophysiologie = Tropical Biome and ImmunoPhysiopathology [Lille] (TBIP), Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS)-Université de Guyane (UG), Centre National de Référence des Leishmanioses - Laboratoire Associé de Cayenne = National Reference Centre for Cutaneous Leishmaniasis (associate laboratory) [Cayenne], Laboratoire de Parasitologie Mycologie, Biologie, Génétique et Pathologie des Pathogènes Eucaryotes (MIVEGEC-BioGEPPE), Pathogènes, Environnement, Santé Humaine (EPATH), Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (MIVEGEC), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud])-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud])-Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (MIVEGEC), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud])-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud]), Centre National de Référence des Leishmanioses [CHRU Montpellier] (CNR-L), Université de Montpellier (UM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service de parasitologie - mycologie [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), This work did not receive any specific funding but received routine funding from the National Reference Centre for Leishmaniasis., Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Génétique et évolution des maladies infectieuses (GEMI), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud])-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud])-Génétique et évolution des maladies infectieuses (GEMI), Service de Parasitologie - Mycologie [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Gestionnaire, HAL Sorbonne Université 5
Subjects: Microbiology (medical), [SDV.IMM] Life Sciences [q-bio]/Immunology, 030231 tropical medicine, Leishmaniasis, Cutaneous, Real-Time Polymerase Chain Reaction, Sensitivity and Specificity, law.invention, 03 medical and health sciences, symbols.namesake, cutaneous leishmaniasis, 0302 clinical medicine, Cutaneous leishmaniasis, law, parasitic diseases, medicine, Humans, 030212 general & internal medicine, Sanger sequencing, biology, business.industry, Sampling (statistics), Diagnostic test, DNA, Protozoan, South America, medicine.disease, Leishmania, biology.organism_classification, Virology, French Guiana, 3. Good health, neglected tropical disease, Real-time polymerase chain reaction, PCR, diagnostic test, symbols, [SDV.IMM]Life Sciences [q-bio]/Immunology, Parasitology, Cotton swab, Restriction fragment length polymorphism, business, Polymorphism, Restriction Fragment Length
Abstract: Recent studies have highlighted the interest in noninvasive sampling procedures coupled with real-time PCR methods for the detection of Leishmania species in South America. In French Guiana, the sampling method still relied on skin biopsies. Noninvasive protocols should be tested on a large annual cohort to improve routine laboratory diagnosis of cutaneous leishmaniasis. Therefore, we evaluated the performance of a new Leishmania detection and species identification protocol involving cotton swabs and SYBR green-based real-time PCR of the Hsp70 gene, coupled with Sanger sequencing., Recent studies have highlighted the interest in noninvasive sampling procedures coupled with real-time PCR methods for the detection of Leishmania species in South America. In French Guiana, the sampling method still relied on skin biopsies. Noninvasive protocols should be tested on a large annual cohort to improve routine laboratory diagnosis of cutaneous leishmaniasis. Therefore, we evaluated the performance of a new Leishmania detection and species identification protocol involving cotton swabs and SYBR green-based real-time PCR of the Hsp70 gene, coupled with Sanger sequencing. Between May 2017 and May 2018, 145 patients with ulcerated lesions compatible with cutaneous leishmaniasis were included in the study at the Cayenne Hospital and its remote health centers. Each patient underwent scrapings for a smear, skin biopsies for parasite culture and PCR-restriction fragment length polymorphism (RFLP) (RNA polymerase II), and sampling with a cotton swab for SYBR green-based PCR. The most accurate diagnostic test was the SYBR green-based PCR on swab samples, showing 98% sensitivity. The mean PCR cycle threshold (CT) was 24.4 (minimum CT, 17; maximum CT, 36) and was
Published: 2021
Full Text: View/download PDF

34. Une approche pour regrouper des sujets atteints de cancers, sur la base des similarités des répartitions cellulaires au sein de leurs biopsies

Author: El Ouahidi, Yassine, Feller, Matis, Talagas, Matthieu, Pasdeloup, Bastien, Pasdeloup, Bastien, IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT), Laboratoire sur les interactions Epithéliums Neurones (LIEN), Université de Brest (UBO), CHRU de Brest - Département de dermatologie, Hôpital Morvan - CHRU de Brest (CHU - BREST ), Département Logique des Usages, Sciences sociales et Sciences de l'Information (IMT Atlantique - LUSSI), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Equipe DECIDE (Lab-STICC_DECIDE), Laboratoire des sciences et techniques de l'information, de la communication et de la connaissance (Lab-STICC), École Nationale d'Ingénieurs de Brest (ENIB)-Université de Bretagne Sud (UBS)-Université de Brest (UBO)-École Nationale Supérieure de Techniques Avancées Bretagne (ENSTA Bretagne)-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS)-Université Bretagne Loire (UBL)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), and Institut Mines-Télécom [Paris] (IMT)-École Nationale d'Ingénieurs de Brest (ENIB)-Université de Bretagne Sud (UBS)-Université de Brest (UBO)-École Nationale Supérieure de Techniques Avancées Bretagne (ENSTA Bretagne)-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS)-Université Bretagne Loire (UBL)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique)
Subjects: histogrammes, [INFO.INFO-LG]Computer Science [cs]/Machine Learning [cs.LG], distance de Wasserstein, [SDV.CAN] Life Sciences [q-bio]/Cancer, analyse de survie, [SDV.CAN]Life Sciences [q-bio]/Cancer, [INFO.INFO-LG] Computer Science [cs]/Machine Learning [cs.LG], Cancer, clustering
Abstract: Extended version in English: https://arxiv.org/abs/2007.00135, In this paper, we introduce a novel and interpretable methodology to cluster subjects suffering from cancer, based on features extracted from their biopsies. Contrary to existing approaches, we propose here to capture complex patterns in the repartitions of their cells using histograms, and compare subjects on the basis of these repartitions. We describe here our complete workflow, including creation of the database, cells segmentation and phenotyping, computation of complex features, choice of a distance function between features, clustering between subjects using that distance, and survival analysis of obtained clusters. We illustrate our approach on a database of hematoxylin and eosin (H&E)-stained tissues of subjects suffering from Stage I lung adenocarcinoma, where our results match existing knowledge in prognosis estimation with high confidence., Nous présentons une méthodologie interprétable pour regrouper des sujets souffrant de cancer, basée sur des attributs extraits d'images numériques de leurs biopsies. Nous proposons d'analyser des répartitions cellulaires à l'aide d'histogrammes, et de comparer les sujets via ceux-ci. Nous décrivons ici la méthodologie pour définir ces histogrammes et les exploiter à des fins de clustering. Nous illustrons notre approche sur une base de données de tissus colorés à l'hématoxyline et à l'éosine de sujets atteints d'un adénocarcinome pulmonaire de stade I, où nos résultats coincident avec les connaissances existantes en matière d'estimation du pronostic de survie, avec une confiance statistique élevée.
Published: 2021

35. In vivo characterization of healthy human skin with a novel, non‐invasive imaging technique: line‐field confocal optical coherence tomography

Author: J.-L. Perrot, J. Perez, Joseph Malvehy, V. Del Marmol, O. Yélamos, M. Miyamoto, J. Monnier, Pietro Rubegni, Linda Tognetti, Elisa Cinotti, C. Orte Cano, S. Puig, Arnaud Dubois, Mariano Suppa, M. Fontaine, Département de dermatologie, CHU Marseille, CHU Marseille, Laboratoire Charles Fabry / Biophotonique, Laboratoire Charles Fabry (LCF), Institut d'Optique Graduate School (IOGS)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Institut d'Optique Graduate School (IOGS)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), and Department of Dermatology, University Hospital of Saint-Etienne
Subjects: Adult, Keratinocytes, Male, Confocal, Human skin, Dermatology, 01 natural sciences, 010309 optics, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Optical coherence tomography, 0103 physical sciences, medicine, Stratum corneum, Humans, ComputingMilieux_MISCELLANEOUS, Skin, [PHYS.PHYS.PHYS-OPTICS]Physics [physics]/Physics [physics]/Optics [physics.optics], integumentary system, medicine.diagnostic_test, business.industry, Histological Techniques, Cheek, Infectious Diseases, medicine.anatomical_structure, Dermal papillae, Female, Epidermis, Tomography, business, Tomography, Optical Coherence, Biomedical engineering
Abstract: Background Line-field confocal optical coherence tomography (LC-OCT) is a non-invasive optical technique recently developed for skin examination in vivo. It provides real-time, high-resolution vertical images with an isotropic resolution of similar to 1 mu m and a penetration depth of similar to 500 mu m. Objectives Study goals were to qualitatively/quantitatively characterize healthy skin at different body sites using LC-OCT. Methods The skin of young healthy volunteers was imaged with a handheld LC-OCT imaging device. Seven body sites (back of the hand, forehead, cheek, nose, chest, forearm and back) were investigated. An independent qualitative [cutaneous structures' description; visibility of keratinocytes' nuclei and dermal-epidermal junction (DEJ)] and quantitative [stratum corneum (SC)/epidermal thicknesses; height of dermal papillae] assessment of the LC-OCT images was performed. Results A total of 88 LC-OCT images were collected from 29 participants (20 females; nine males; mean age 25.9 years). Keratinocytes' nuclei and DEJ were visible in the totality of images. The different layers of the epidermis and the remaining cutaneous structures/findings were visualized. Body sites-related variability was detected for SC/epidermal thicknesses and height of dermal papillae. Inter-observer agreement was excellent (SC thickness), good-to-excellent (epidermal thickness) and moderate-to-good (papillae). Conclusions Line-field confocal-OCT provides non-invasive, real-time imaging of the skin in vivo with deep penetration and high resolution, enabling the visualization of single cells. The histology-like vertical view provides an easy way to recognize/measure different cutaneous structures/findings. LC-OCT appears as a promising technique for the examination of physiological/pathological skin.
Published: 2020
Full Text: View/download PDF

36. Epidemiology of cutaneous involvement in Sjögren syndrome: Data from three French pSS populations (TEARS, ASSESS, diapSS)

Author: Raphaèle Seror, Laurent Misery, Philippe Dieudé, Eric Hachulla, Xavier Mariette, Gilles Hayem, Jacques-Eric Gottenberg, Camille Villon, Aleth Perdriger, Laure Orgeolet, Jean-Jacques Dubost, Divi Cornec, Jacques Morel, Pierre-Yves Hatron, Jean-Marie Berthelot, Vincent Goëb, Anne-Laure Fauchais, Valérie Devauchelle-Pensec, Véronique Le Guern, Sandrine Jousse-Joulin, Olivier Vittecoq, Claire Larroche, Alain Saraux, Anne-Marie Roguedas, CHRU de Brest - Département de dermatologie, Hôpital Morvan - CHRU de Brest (CHU - BREST ), Service de dermatologie (Dermato - BREST), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Service de rhumatologie [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Rhumatologie (Rhumato - BICHAT), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Rhumatologie [CHU Gabriel-Montpied], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Service de Médecine interne A et polyclinique médicale [CHU Limoges], CHU Limoges, Service de Rhumatologie - AMIENS (AMIENS - Rhumato), CHU Amiens-Picardie, Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Oust de France (CeRAINO), F-59000, Lille, Service de médecine interne [Avicenne], Hôpital Avicenne [AP-HP], Département de Rhumatologie (Rhumato - Ambroise Paré - PARIS), Centre Hospitalier Universitaire Ambroise Paré (CHU Ambroise Paré), Service de médecine interne et centre de référence des maladies rares [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de rhumatologie [Rennes] = Rheumatology [Rennes], CHU Pontchaillou [Rennes], Unité thérapeutique d'immunologie clinique et des maladies ostéoarticulaires [Hôpital Lapeyronie, Montpellier], Hôpital Lapeyronie [Montpellier] (CHU), Service de rhumatologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), and Centre National de Référence CERAINO, Service de Rhumatologie (Hôpital de la Cavale Blanche)
Subjects: medicine.medical_specialty, Visual analogue scale, Placebo, Severity of Illness Index, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Internal medicine, Dry skin, medicine, Prevalence, Humans, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Pain Measurement, 030203 arthritis & rheumatology, integumentary system, business.industry, Hypergammaglobulinemia, medicine.disease, Dermatology, eye diseases, 3. Good health, stomatognathic diseases, Sjogren's Syndrome, Cohort, Tears, [SDV.IMM]Life Sciences [q-bio]/Immunology, Rituximab, medicine.symptom, business, medicine.drug
Abstract: To determine the prevalence and significance of dermatological disorders in primary Sjögren syndrome (pSS).We used 2 pSS French cohorts (ASSESS, in which prevalence of skin disorders in 395 patients was evaluated; and diapSS, in which 76 on 139 pSS patients had an examination by a dermatologist) and baseline data of the TEARS randomized trial (110 patients with recent or active pSS treated with rituximab or placebo and evaluated for skin dryness using a visual analogue scale (VAS) out of 100).Skin manifestations included in the EULAR Sjögren syndrome disease activity index (ESSDAI) were rare in the ASSESS cohort (n=16/395, 4.1%, mainly purpuras; only 3 had high activity), but they were associated with activity in the other ESSDAI domains (peripheral neurological (P0.001), muscular (P0.01), haematological (P0.05), biological (P0.05), history of arthritis (P0.01), splenomegaly (P0.05) and higher gamma globulin levels (P0.01)). In the diapSS cohort, compared to pSS patients not receiving a dermatological consultation, the pSS patients who had a dermatological consultation had significantly more dermatological involvement outside the ESSDAI score [38.2% (29/76) versus 15.9% (10/63); P0.01]. The TEARS study showed a high prevalence of cutaneous dryness (VAS50; 48.2%) and found that patients with dry skin had higher VAS pain (P0.01) and drought (P0.01) scores.ESSDAI skin activity is rare and associated with hypergammaglobulinemia and ESSDAI activity. Systematic dermatological examination is informative for non-specific lesions. The most common skin disorder is skin dryness, which is associated with a higher pain and overall subjective dryness.
Published: 2020
Full Text: View/download PDF

37. PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy

Author: Valentin Voillet, Tiffany Beauvais, Brigitte Dréno, Charles Nardin, Régis Josien, Camille Dabrowski, Nathalie Labarrière, Stanley R. Riddell, Sylvain Simon, Candice D. Church, Nicolas Jouand, Raphael Gottardo, Olivier Adotevi, Amir Khammari, François Aubin, Steven P. Fling, Cécile Braudeau, Martin A. Cheever, Virginie Vignard, Paul Nghiem, Samuel Rulli, Nirasha Ramchurren, Caroline Laheurte, Zhong Wu, Anti-Tumor Immunosurveillance and Immunotherapy (CRCINA-ÉQUIPE 3), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), LabEX IGO Immunothérapie Grand Ouest, Fred Hutchinson Cancer Research Center [Seattle] (FHCRC), Centre hospitalier universitaire de Nantes (CHU Nantes), Qiagen Sciences [Frederick, MD, USA], Plateforme CYTOCELL Nantes (CRCINA-CYTOCELL), Clinical and Translational Research in Skin Cancer (CRCINA-ÉQUIPE 2), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Université de Nantes (UN)-Université de Nantes (UN), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de dermatologie (CHRU Besançon), Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), SIRIC ILIAD (INCA-DGOS-Inserm_12558)BMS FoundationLigue contre le CancerRégion Pays de la Loire, ANR-11-LABX-0016,IGO,Immunothérapies Grand Ouest(2011), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Nantes Université (Nantes Univ), Département de dermatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), LABARRIERE, Nathalie, and Laboratoires d'excellence - Immunothérapies Grand Ouest - - IGO2011 - ANR-11-LABX-0016 - LABX - VALID
Subjects: 0301 basic medicine, Cancer Research, medicine.medical_treatment, Programmed Cell Death 1 Receptor, CD8-Positive T-Lymphocytes, 0302 clinical medicine, T-Lymphocyte Subsets, Immunotherapy Biomarkers, Immunology and Allergy, Cytotoxic T cell, Receptors, Immunologic, Immune Checkpoint Inhibitors, RC254-282, education.field_of_study, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 3. Good health, medicine.anatomical_structure, Oncology, [SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology, [SDV.IMM.IA] Life Sciences [q-bio]/Immunology/Adaptive immunology, 030220 oncology & carcinogenesis, Molecular Medicine, immunotherapy, [SDV.IMM.IMM] Life Sciences [q-bio]/Immunology/Immunotherapy, Receptors, CXCR5, costimulatory and inhibitory T-Cell receptors, T cell, Immunology, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Biology, 03 medical and health sciences, Immune system, [SDV.CAN] Life Sciences [q-bio]/Cancer, TIGIT, Predictive Value of Tests, medicine, melanoma, Humans, education, Pharmacology, Immunotherapy, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, Gene signature, Carcinoma, Merkel Cell, 030104 developmental biology, Cancer research, CD8
Abstract: BackgroundClinical benefit from programmed cell death 1 receptor (PD-1) inhibitors relies on reinvigoration of endogenous antitumor immunity. Nonetheless, robust immunological markers, based on circulating immune cell subsets associated with therapeutic efficacy are yet to be validated.MethodsWe isolated peripheral blood mononuclear cell from three independent cohorts of melanoma and Merkel cell carcinoma patients treated with PD-1 inhibitor, at baseline and longitudinally after therapy. Using multiparameter flow cytometry and cell sorting, we isolated four subsets of CD8+ T cells, based on PD-1 and TIGIT expression profiles. We performed phenotypic characterization, T cell receptor sequencing, targeted transcriptomic analysis and antitumor reactivity assays to thoroughly characterize each of these subsets.ResultsWe documented that the frequency of circulating PD-1+TIGIT+ (DPOS) CD8+ T-cells after 1 month of anti-PD-1 therapy was associated with clinical response and overall survival. This DPOS T-cell population was enriched in highly activated T-cells, tumor-specific and emerging T-cell clonotypes and T lymphocytes overexpressing CXCR5, a key marker of the CD8 cytotoxic follicular T cell population. Additionally, transcriptomic profiling defined a specific gene signature for this population as well as the overexpression of specific pathways associated with the therapeutic response.ConclusionsOur results provide a convincing rationale for monitoring this PD-1+TIGIT+ circulating population as an early cellular-based marker of therapeutic response to anti-PD-1 therapy.
Published: 2020
Full Text: View/download PDF

38. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau

Author: Denis Jullien, Marie Aleth Richard, Julien Seneschal, F. Aubin, S. Hegazy, Michel D'Incan, E. Mahé, Coralie Barbe, Céline Girard, B. Husson, Emilie Brenaut, Hervé Bachelez, Curdin Conrad, Emilie Sbidian, M. Viguier, Centre Hospitalier Universitaire de Reims (CHU Reims), Immuno-Régulation dans les Maladies Auto-Immunes Inflammatoires et le Cancer - EA 7509 (IRMAIC), Université de Reims Champagne-Ardenne (URCA), Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Dermatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Service de Dermatologie et pathologies vasculaires [CH Argenteuil], Centre Hospitalier Victor Dupouy, Institut Laue-Langevin (ILL), ILL, Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Service de dermatologie, Hôpital Augustin Morvan-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Laboratoire de biologie cellulaire et moléculaire, Institut National de la Recherche Agronomique (INRA), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Robert Debré, CRCM, Université Paris7, Assistance Publique - Hôpitaux de Paris, Département de dermatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)
Subjects: Male, medicine.medical_specialty, Palmoplantar pustulosis, [SDV]Life Sciences [q-bio], education, [SDV.CAN]Life Sciences [q-bio]/Cancer, Dermatology, Gastroenterology, Etanercept, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Psoriasis, Internal medicine, Ustekinumab, parasitic diseases, Adalimumab, medicine, otorhinolaryngologic diseases, Humans, ComputingMilieux_MISCELLANEOUS, Retrospective Studies, business.industry, Acrodermatitis, Odds ratio, medicine.disease, Infliximab, 3. Good health, Infectious Diseases, 030220 oncology & carcinogenesis, [SDV.IMM]Life Sciences [q-bio]/Immunology, Tumor Necrosis Factor Inhibitors, business, medicine.drug
Abstract: Background Palmoplantar pustulosis (PPP) and acrodermatitis continua of Hallopeau (ACH) are rare variants of psoriasis. Knowledge of the efficacy of biologics is scarce. Objectives To evaluate the real-life efficacy of tumour necrosis factor blockers and ustekinumab in PPP and in ACH. Methods A multicentre retrospective descriptive study was conducted in 19 dermatology departments, including all patients with PPP or ACH seen from 2014 to 2016 who received one of the studied biologics. The data were collected by a standardized document. Factors associated with complete clearance (CC) were analysed by multivariate analysis, estimating odds ratios (ORs) and 95% confidence intervals (CIs). Results Among 92 patients included, 50 received adalimumab, 44 ustekinumab, 36 etanercept and 31 infliximab. Improvement and CC were observed in 83.9% and 20.0% patients receiving infliximab, 75.0% and 38.6% ustekinumab, 57.1% and 20.0% etanercept and 60.4% and 29.2% adalimumab. We found no significant difference in CC rates or duration of treatment among the biological treatments (P = 0.18 and P = 0.10, respectively). On multivariate analysis, CC with etanercept was associated with the ACH form and not smoking [OR = 9.5 (95% CI 1.1-82.7), P = 0.04 and 0.1 (0.01-0.9), P = 0.04]; with ustekinumab, male sex and absence of obesity [6.0 (1.3-28.6), P = 0.02 and 4.7 (1.0-22.7), P = 0.05]; with adalimumab, the ACH form [11.9 (2.7-52.3), P = 0.001]; and with infliximab, obesity [5.6 (1.1-29.4), P = 0.04]. Conclusions We found no difference in efficacy between TNF blockers and ustekinumab and among the three different TNF blockers in real life for PPP or ACH, which reveals the heterogeneity of clinical response to biologics in pustular psoriasis as compared with plaque psoriasis.
Published: 2020
Full Text: View/download PDF

39. Comment on ‘Cutaneous manifestations in COVID‐19: a first perspective’ by Recalcati S

Author: F. Cazenave-Roblot, E. Hainaut, M. Masson Regnault, M. Hedou, F. Carsuzaa, E. Chary, Département de Dermatologie [CHU Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Médecine Interne et Maladies Infectieuses, CHU de Poitiers, Poitiers, France, Pharmacologie des anti-infectieux (PHAR), Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM), and Chauzy, Alexia
Subjects: medicine.medical_specialty, skin, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), [SDV]Life Sciences [q-bio], Pneumonia, Viral, Anosmia, COVID‐19 infections, Dermatology, Skin Diseases, Letter to Editor, Betacoronavirus, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Pandemic, Humans, Medicine, Letters to Editor, Pandemics, rhinorrhea, SARS-CoV-2, business.industry, COVID-19, Outbreak, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, 3. Good health, Dysgeusia, [SDV] Life Sciences [q-bio], [SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciences, Cutaneous manifestations, Infectious Diseases, Chinese city, 030220 oncology & carcinogenesis, medicine.symptom, Coronavirus Infections, business
Abstract: International audience; Since the coronavirus disease 2019 (COVID 19) outbreak was first reported in the Chinese city of Wuhan on December 31, 2019, it has stricken more than 1,000,000 persons worldwide, of whom over 50,000 have died (1). Having been infected by severe acute respiratory syndrome coronavirus 2 (SARS‐COV‐2), patients with COVID‐19 mainly present with fever and respiratory symptoms (2). Isolated sudden onset anosmia has also frequently been reported (3). Less frequently, rhinorrhea, diarrhoea and dysgeusia may be associated. While only a few reports have evoked cutaneous manifestations (4), we read with interest an initial study on the topic entitled “Cutaneous manifestations in COVID‐19: a first perspective ” by Recalcati S. (5).
Published: 2020
Full Text: View/download PDF

40. No antibody response in acral cutaneous manifestations associated with COVID‐19 ?

Author: R. Mahieu, Y. Le Corre, E. Vinatier, Yves Marie Vandamme, Anne Croue, L. Tillard, H. Le Guillou-Guillemette, Pascale Jeannin, ATOMycA (CRCINA-ÉQUIPE 6), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Service des maladies infectieuses et tropicales [CHU Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), Innate Immunity and Immunotherapy (CRCINA-ÉQUIPE 7), Laboratoire d'Immunologie [CHU Angers], Département de Pathologie [CHU Angers], LUNAM Université [Nantes Angers Le Mans], Département de dermatologie [CHU Angers], Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), and Bernardo, Elizabeth
Subjects: Male, Antibodies, Viral, Severe Acute Respiratory Syndrome, Letter to Editor, law.invention, Serology, perniosis, Cohort Studies, 030207 dermatology & venereal diseases, 0302 clinical medicine, law, 030212 general & internal medicine, Polymerase chain reaction, biology, medicine.diagnostic_test, Biopsy, Needle, Middle Aged, Prognosis, Immunohistochemistry, 3. Good health, acral lesions, Infectious Diseases, Female, Antibody, Coronavirus Infections, chilblain, Adult, medicine.medical_specialty, Lichenoid Eruptions, Coronavirus disease 2019 (COVID-19), Pneumonia, Viral, [SDV.CAN]Life Sciences [q-bio]/Cancer, Dermatology, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, COVID‐19, Biopsy, medicine, Humans, cutaneous manifestations Manuscript word count: 598 Figure count: 1, Pandemics, cutaneous manifestations, business.industry, Acrodermatitis, COVID-19, medicine.disease, Reverse transcriptase, Pneumonia, biology.protein, business
Abstract: International audience; Skins symptoms during COVID‐19 have been recently described but their relation to SARS‐CoV‐2 is unclear while results for real‐time reverse transcriptase polymerase chain reaction (rRT‐PCR) testing were variable. Recalcati et al. reported 14 cases of patients with skin symptoms consistent with previous described COVID‐19 lesions but all the patients were tested negative. They asked for a serology to validate the hypothesis that these lesions are related to COVID‐19.
Published: 2020
Full Text: View/download PDF

41. Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France

Author: Z. Reguiai, A. Tournier, M. Amy de la Bretèque, A. Beauchet, A. Khemis, François Maccari, E. Mahé, Gem Resopso, M. Bastien, Anne-Claire Fougerousse, J. Parier, Valérie Pallure, T. Boyé, Nathalie Beneton, Edouard Begon, Martine Avenel-Audran, Céline Girard, J.-L. Perrot, Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM), Département de dermatologie, CHU Angers, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Centre Hospitalier Saint Jean de Perpignan, and Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne)
Subjects: Adult, Male, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Dermatology, law.invention, 030207 dermatology & venereal diseases, 03 medical and health sciences, Folic Acid, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Psoriasis, medicine, Humans, Prospective Studies, Prospective cohort study, Adverse effect, ComputingMilieux_MISCELLANEOUS, business.industry, Cumulative dose, Middle Aged, medicine.disease, 3. Good health, Methotrexate, Treatment Outcome, Concomitant, Multivariate Analysis, Cyclosporine, Female, Dermatologic Agents, France, business, Rheumatism, medicine.drug
Abstract: Methotrexate (MTX) is a major systemic treatment for moderate to severe plaque psoriasis. A randomized trial has recently been published evaluating a single weekly dosage (17.5mg), but few prospective real-life data are available. The main objective of this study was to prospectively evaluate the efficacy of MTX in real-life. The secondary objectives were to evaluate predictive parameters for treatment efficacy and the frequency of adverse events.A prospective cohort involving consecutive at in 25 centres belonging to GEM RESOPSO included all adults with plaque psoriasis in whom MTX treatment was initiated. The efficacy criterion was achievement of PASI 75 at week (W) 12/16. The impact of demographic data, psoriasis characteristics (duration, topography, rheumatism), dosage (W12/16 dosage, cumulative dose after 4 weeks), and mode of administration (subcutaneous vs. oral, concomitant use of folic acid) on efficacy was evaluated. Intention-to-treat (ITT),per protocol (PP), and multivariate analyses were performed.Two hundred and fifty-six patients (F/M: 105/151; mean age: 45.0 years; rheumatism: 12.6%) with plaque psoriasis were included. 99 patients were not analysed at W12/16 (16 because of inefficacy, 16 because of intolerance, 56 were lost to follow-up or had data missing). PASI 75 was achieved in 98 patients, with efficacy of 38.3% in the ITT analysis and 58.3% in the PP analysis. In the ITT analysis, absence of previous use of cyclosporine (P=0.01) and a cumulative dose of MTX60mg after 4 weeks (P0.0001) were associated with higher PASI 75 rates. In the PP analysis, only absence of previous use of cyclosporine (P=0.0009) was associated with a better PASI 75 results. There was no association between PASI 75 and patient characteristics (including body mass index), clinical aspects of psoriasis, route of administration, combination with folic acid, or W12/16 dose. Adverse events were reported by 34.8% of patients. These consisted mainly of digestive disorders (nausea, abdominal pain), asthenia and moderate hepatic cytolysis. The frequency of adverse events was correlated with methotrexate dosage.The efficacy of MTX in plaque psoriasis in this real-life study of 256 patients is consistent with the data in the literature, including the recently published randomized trial (41% PASI 75). This rate was unaffected by patient weight, route of administration and combined use of folic acid. Absence of previous use of cyclosporine appears to be associated with better efficacy although there is no clear explanation for this. The initial dosage (high dose in the first month) appears to be associated with superior efficacy for W12/W16.
Published: 2019
Full Text: View/download PDF

42. Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy

Author: Mignard, Claire, Maho-Vaillant, Maud, Golinski, Marie-Laure, Balayé, Pierre, Prost-Squarcioni, Catherine, Houivet, Estelle, Calbo, Sé Bastien, Labeille, Bruno, Picard-Dahan, Catherine, Konstantinou, Maria Polina, Chaby, Guillaume, Richard, Marie-Aleth, Bouaziz, Jean-David, Duvert-Lehembre, Sophie, Delaporte, Emmanuel, Bernard, Philippe, Caux, Frédéric, Alexandre, Marina, Ingen-Housz-Oro, Saskia, Vabres, Pierre, Quéreux, Gaelle, Dupuy, Alain, Debarbieux, Sebastien, Avenel-Audran, Martine, d'Incan, Michel, Bedane, Christophe, Beneton, Nathalie, Jullien, Denis, Dupin, Nicolas, Misery, Laurent, Machet, Laurent, Beylot-Barry, Marie, Dereure, Olivier, Sassolas, Bruno, Bénichou, Jacques, Joly, Pascal, Hebert, Vivien, Calbo, Sébastien, Service de dermatologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de Dermatologie [Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Service de dermatologie [Paris], Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Unité de biostatistiques [CHU Rouen], University Hospital of St-Etienne, Department of Dermatology, Service de Dermatologie, Hôpital Bichat, AP-HP, Service de dermatologie [CHU d'Amiens-Picardie], CHU Amiens-Picardie, Département de dermatologie, CHU Marseille, CHU Marseille, Service de Dermatologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), Hôpital Claude Huriez [Lille], CHU Lille, Immunodermatologie, Cytokines, Cancer - EA 7319 (ICA), Université de Reims Champagne-Ardenne (URCA), Service de dermatologie [Avicenne], Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Henri Mondor, Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Clinical and Translational Research in Skin Cancer (CRCINA-ÉQUIPE 2), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Service de Dermatologie [Rennes] = Dermatology [Rennes], CHU Pontchaillou [Rennes], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Service de Dermatologie, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Clermont-Ferrand, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Service de Dermatologie [CHU Limoges], CHU Limoges, Centre Hospitalier Le Mans (CH Le Mans), Club Rhumatismes et Inflammation, EA1833, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Service de dermatologie, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Bordeaux [Bordeaux], Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Normandie Université (NU)-Normandie Université (NU)-Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Hôpital Charles Nicolle [Rouen], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Service de Dermatologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)-Université Jean Monnet - Saint-Étienne (UJM), Immuno-Régulation dans les Maladies Auto-Immunes Inflammatoires et le Cancer - EA 7509 (IRMAIC), CHU Henri Mondor [Créteil], Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
Subjects: integumentary system, immune system diseases, [SDV]Life Sciences [q-bio], education, [SDV.CAN]Life Sciences [q-bio]/Cancer, macromolecular substances
Abstract: International audience; Importance: Rituximab and short-term corticosteroid therapy are the criterion standard treatments for patients with newly diagnosed moderate to severe pemphigus.Objective: To examine factors associated with short-term relapse in patients with pemphigus treated with rituximab.Design, setting, and participants: This post hoc analysis of a randomized clinical trial (Comparison Between Rituximab Treatment and Oral Corticosteroid Treatment in Patients With Pemphigus [RITUX 3]) conducted from January 1, 2010, to December 31, 2015, included patients from 20 dermatology departments of tertiary care centers in France from the RITUX 3 trial and 3 newly diagnosed patients treated according to the trial protocol. Data analysis was performed from February 1 to June 30, 2019.Exposure: Patients randomly assigned to the rituximab group in the RITUX 3 trial and the 3 additional patients were treated with 1000 mg of intravenous rituximab on days 0 and 14 and 500 mg at months 12 and 18 combined with a short-term prednisone regimen.Main outcomes and measures: Baseline (pretreatment) clinical and biological characteristics (Pemphigus Disease Area Index [PDAI] score, ranging from 0-250 points, with higher values indicating more severe disease) and changes in anti-desmoglein (DSG) 1 and anti-DSG3 values as measured by enzyme-linked immunosorbent assay during the 3 months after rituximab treatment were compared between patients with disease relapse and those who maintained clinical remission during the first 12 months after treatment. The positive and negative predictive values of these factors were calculated.Results: Among 47 patients (mean [SD] age, 54.3 [17.0] years; 17 [36%] male and 30 [64%] female) included in the study, the mean (SD) baseline PDAI score for patients with relapsing disease was higher than that of the patients with nonrelapsing disease (54 [33] vs 28 [24]; P = .03). At month 3, 7 of 11 patients with relapsing disease (64%) vs 7 of 36 patients with nonrelapsing disease (19%) had persistent anti-DSG1 antibody values of 20 IU/mL or higher and/or anti-DSG3 antibody values of 130 IU/mL or higher (P = .01). A PDAI score of 45 or higher defining severe pemphigus and/or persistent anti-DSG1 antibody values of 20 IU/mL or higher and/or anti-DSG3 antibody values of 130 IU/mL or higher at month 3 provided a positive predictive value of 50% (95% CI, 27%-73%) and a negative predictive value of 94% (95% CI, 73%-100%) for the occurrence of relapse after rituximab.Conclusions and relevance: The findings suggest that initial PDAI score and changes in anti-DSG antibody values after the initial cycle of rituximab might help differentiate a subgroup of patients with high risk of relapse who might benefit from maintenance rituximab infusion at month 6 from a subgroup of patients with low risk of relapse who do not need early maintenance therapy.Trial registration: NCT00784589.
Published: 2020
Full Text: View/download PDF

43. Large International Validation of ABSIS and PDAI Pemphigus Severity Scores

Author: Hébert, Vivien, Boulard, Claire, Houivet, Estelle, Lehembre, Sophie, Borradori, Luca, Della, Rocco, Feliciani, Claudio, Fania, Luca, Zambruno, Giovanna, Camaioni, Diana, Didona, Biago, Marinovic, Branka, Schmidt, Enno, Schumacher, Nina, Hü Nefeld 10, Christian, Schanz, Stefan, Kern, Johannes, Hofmann, Silke, Bouyeure, Anne, Picard-Dahan, Catherine, Prost-Squarcioni, Catherine, Caux, Frederic, Alexandre, Marina, Ingen-Housz-Oro, Saskia, Bagot, Martine, Tancrede-Bohin, Emmanuelle, David Bouaziz, Jean, Franck, Nathalie, Vabres, Pierre, Labeille, Bruno, Richard, Marie, Delaporte, Emmanuel, Dupuy, Alain, D'Incan, Michel, Quereux, Gaelle, Skowro, François, Paul, Carle, Livideanu, Cristina, Beylot-Barry, Marie, Doutre, Marie, Avenel-Audran, Martine, Bedane, Christophe, Bernard, Philippe, Machet, Laurent, Maillard, Hervé, Jullien, Denis, Debarbieux, Sebastien, Sassolas, Bruno, Misery, Laurent, Abasq, Claire, Dereure, Olivier, Lagoutte, Philippe, Ferranti, Vincent, Werth, Victoria, Murrell, Dedee, Hertl, Michael, Benichou, Jacques, Joly, Pascal, Duvert Lehembre, Sophie, Della Torre, Rocco, Hünefeld, Christian, Kern, Johannes Steffen, Bouyeure, Anne Charlotte, Bouaziz, Jean David, Richard, Marie Aleth, D’Incan, Michel, Livideanu, Cristina Bulai, Doutre, Marie Sylvie, UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Pharmacoepidemiologie et évaluation de l'impact des produits de santé sur les populations, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Bordeaux Segalen - Bordeaux 2-Université de Rouen Normandie (UNIROUEN), Universität Bern [Bern], Molecular and Cell Biology Laboratory, IDI-IRCCS, Rome, Service de Dermatologie, Hôpital Bichat, AP-HP, Service de dermatologie [Paris], Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Service de dermatologie [Avicenne], Hôpital Avicenne-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris 13 (UP13), CHU Henri Mondor, Service de Dermatologie [AP-HP Hôpital Saint Louis, Paris], Université Paris Diderot - Paris 7 (UPD7)-AP-HP Hôpital Saint-Louis, Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), University Hospital of St-Etienne, Department of Dermatology, Université Grenoble Alpes - UFR Pharmacie (UGA UFRP), Université Grenoble Alpes (UGA), Service de dermatologie (CHRU de Lille), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Dermatologie [Rennes], CHU Pontchaillou [Rennes], Imagerie Moléculaire et Stratégies Théranostiques - Clermont Auvergne (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Service de dermatologie [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Département de Dermatologie, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de Dermatologie [CHU Limoges], CHU Limoges, Club Rhumatismes et Inflammation, Service de Dermatologie, Centre Hospitalier Sud, Hospices Civils, Lyon, Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Service de dermatologie (Dermato - BREST), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Génétique médicale et fonctionnelle du cancer et des maladies neuropsychiatriques, Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie et biothérapies des maladies inflammatoires et autoimmunes, Seventh Framework Programme, French Society of Dermatology, Centre Hospitalier Universitaire de Reims (CHU Reims), Immuno-Régulation dans les Maladies Auto-Immunes Inflammatoires et le Cancer - EA 7509 (IRMAIC), Université de Reims Champagne-Ardenne (URCA), CHU Rouen, Normandie Université (NU), Service de dermatologie [Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Unité de biostatistiques [Rouen], Service de Dermatologie [Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]-Université Paris Diderot - Paris 7 (UPD7), Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Avicenne, Institut Mondor de recherche biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), L'Oréal recherche et innovation, L'Oréal, Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-IFR140-Centre National de la Recherche Scientifique (CNRS), Service de Dermatologie, Hôtel-Dieu, Centre de Recherche en Cancérologie / Nantes - Angers (CRCNA), Centre hospitalier universitaire de Nantes (CHU Nantes)-Faculté de Médecine d'Angers-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Centre National de la Recherche Scientifique (CNRS)-Hôpital Laennec-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôtel-Dieu de Nantes, Université Toulouse III - Paul Sabatier (UPS), Immunodermatologie, Cytokines, Cancer - EA 7319 (ICA), Service de dermatologie (CHRU de Tours), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), INSERM U1234, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Diderot - Paris 7 (UPD7)-Hopital Saint-Louis [AP-HP] (AP-HP), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Service de Dermatologie [Rennes] = Dermatology [Rennes], Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Université Bordeaux Segalen - Bordeaux 2-Université de Rouen Normandie (UNIROUEN), Universität Bern [Bern] (UNIBE), IDI-IRCCS [Roma, Italy], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], CHU Henri Mondor [Créteil], Service de Dermatologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)-Université Jean Monnet - Saint-Étienne (UJM), Université de Toulouse (UT), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
Subjects: 0301 basic medicine, Autoimmune Bullous Skin Disorder Intensity Score, Intraclass correlation, [SDV]Life Sciences [q-bio], intraclass correlation coefficient, Autoimmunity, PV, Validation Studies as Topic, Severity of Illness Index, Biochemistry, PDAI, 0302 clinical medicine, Medicine, DLQI, Pemphigus foliaceus, Skin, integumentary system, Desmoglein 1, PGA, CI, 3. Good health, ABSIS, month, 030220 oncology & carcinogenesis, PF, medicine.medical_specialty, pemphigus vulgaris, [SDV.CAN]Life Sciences [q-bio]/Cancer, Dermatology, 03 medical and health sciences, Dermatology Quality of Life Index, Internal medicine, Severity of illness, Humans, In patient, pemphigus foliaceus, Molecular Biology, Autoantibodies, Pemphigus severity scores, ICC, business.industry, Pemphigus vulgaris, Cell Biology, medicine.disease, Confidence interval, Moderate extent, Pemphigus Disease Area Index, Pemphigus, 030104 developmental biology, confidence interval, Physician Global Assessment, business, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: IF 6.448 (2017); International audience; The Pemphigus Disease Area Index (PDAI) and Autoimmune Bullous Skin Disorder Intensity-Score (ABSIS) scores have been proposed to provide an objective measure of pemphigus activity. These scores have been evaluated only on already treated patients mainly with mild to moderate activity. The objective was to assess the interrater reliability of ABSIS and PDAI scores and their correlation with other severity markers in a large international study. Consecutive patients with newly diagnosed pemphigus were enrolled in 31 centers. Severity scores were recorded during a 24-month period by the same two blinded investigators. Serum was collected at each visit for ELISA measurement of anti-desmoglein antibodies. The intraclass correlation coefficient (ICC) and Spearman rank correlation coefficient were calculated. A total of 116 patients with pemphigus vulgaris (n = 84) or pemphigus foliaceus (n = 32) were included. At baseline, the ABSIS and PDAI ICCs were 0.90 (95% confidence interval [CI] = 0.85-0.93), and 0.91(95% CI = 0.87-0.94), respectively. The ICCs for PDAI were higher in moderate and extensive pemphigus (ICC = 0.82, 95% CI = 0.63-0.92 and ICC = 0.80, 95% CI = 0.62-0.90, respectively) than in patients with intermediate (significant) extent (ICC = 0.50, 95% CI = 0.27-0.68). Conversely, the ICCs for ABSIS were lower in patients with moderate extent (ICC = 0.44, 95% CI = 0.004-0.74) than in those with intermediate or extensive forms, (ICC = 0.69, 95% CI = 0.51-0.81 and ICC = 0.75, 95% CI = 0.51-0.88, respectively). During patients' follow-up, the ICCs of both ABSIS and PDAI scores remained higher than 0.70. ABSIS and PDAI skin (r = 0.71 and r = 0.75) but not mucosal (r = 0.32 and r = 0.37) subscores were correlated with the evolution of anti-DSG1 and anti-DSG3 ELISA values, respectively. ABSIS and PDAI scores are robust tools to accurately assess pemphigus activity.
Published: 2019
Full Text: View/download PDF

44. Diagnostic biologique des angioedèmes bradykiniques : les recommandations du CREAK

Author: David Launay, Gaëlle Hardy, Guillaume Armengol, Julien Faure, Claire de Moreuil, Bernard Floccard, Frederica Defendi, C. Mansard, Nicolas Marmion, Alban Deroux, Laurence Bouillet, Anne Gompel, Roland Jaussaud, Yann Olliver, Isabelle Boccon-Gibod, Nicolas Javaud, Chantal Dumestre-Pérard, Lucile Sorin, Etienne Beaudouin, Aureli Du Than, Olivier Fain, Fabien Pelletier, Stéphane Gayet, Laurent Sailler, Jean Yves Cesbron, Anne Sarrat, Stephane Guez, Centre National de Reference des Angioedemes à Kinines, CHU Grenoble, Service d'immunologie [CHU Grenoble], CHU de Grenoble, Barrière Naturelle et Infectiosité (TIMC-IMAG-BNI), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Centre Hospitalier Universitaire [Grenoble] (CHU), Service de gynécologie et d'endocrinologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Université de Reims Champagne-Ardenne (URCA), Service d’Allergologie, Centre Hospitalier Emile Durkheim [Epinal] (CH Epinal / CHED), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Hôpital de la Timone [CHU - APHM] (TIMONE), CHU Toulouse [Toulouse], CHU Bordeaux [Bordeaux], Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Département de dermatologie, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Hôpital Saint-Jacques-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Hôpital Louis Mourier - AP-HP [Colombes], Centre Hospitalier Universitaire de La Réunion (CHU La Réunion), Service de Médecine Interne [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Orange Labs [Lannion], and France Télécom
Subjects: 0301 basic medicine, medicine.medical_specialty, MESH: Complement C1 Inhibitor Protein, Bradykinin, MESH: Algorithms, MESH: Angioedemas, Hereditary, MESH: Comorbidity, Context (language use), MESH: Fibrinolysin, MESH: Kallikreins, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, MESH: Pregnancy, 0302 clinical medicine, MESH: Early Diagnosis, MESH: Child, Internal medicine, medicine, MESH: Angioedema, MESH: Hereditary Angioedema Types I and II, MESH: Lupus Erythematosus, Systemic, 030203 arthritis & rheumatology, MESH: Bradykinin, Pregnancy, MESH: Humans, Lupus erythematosus, biology, Angioedema, business.industry, MESH: Symptom Assessment, MESH: Angiotensin-Converting Enzyme Inhibitors, Angiotensin-converting enzyme, General Medicine, MESH: Hematologic Diseases, medicine.disease, 3. Good health, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, 030104 developmental biology, chemistry, MESH: Pregnancy Complications, Hereditary angioedema, biology.protein, Antibody, medicine.symptom, business, MESH: Female, MESH: Factor XII
Abstract: International audience; Bradykinin mediated angioedema (BK-AE) can be associated either with C1Inhibitor deficiency (hereditary and acquired forms), either with normal C1Inh (hereditary form and drug induced AE as angiotensin converting enzyme inhibitors…). In case of high clinical suspicion of BK-AE, C1Inh exploration must be done at first: C1Inh function and antigenemy as well as C4 concentration. C1Inh deficiency is significant if the tests are below 50 % of the normal values and controlled a second time. In case of C1Inh deficiency, you have to identify hereditary from acquired forms. C1q and anti-C1Inh antibody tests are useful for acquired BK-AE. SERPING1 gene screening must be done if a hereditary angioedema is suspected, even if there is no family context (de novo mutation 15 %). If a hereditary BK-AE with normal C1Inh is suspected, F12 and PLG gene screening is suitable.
Published: 2019
Full Text: View/download PDF

45. The impact of atopic dermatitis on sexual health

Author: Laurent Misery, Julien Seneschal, Stéphanie Merhand, F. Huet, Charles Taieb, Khaled Ezzedine, Ziad Reguiai, Stéphane Héas, Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Dermatologie [CHU de Reims], Centre Hospitalier Universitaire de Reims (CHU Reims), Violences, Innovations, Politiques, Socialisations et Sports (VIPS2), Université de Rennes 2 (UR2), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Le Mans Université (UM)-École normale supérieure - Rennes (ENS Rennes), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de dermatologie Hôpital Saint-André Bordeaux, and CHU Bordeaux [Bordeaux]
Subjects: Adult, Male, 0301 basic medicine, Time Factors, [SHS.INFO]Humanities and Social Sciences/Library and information sciences, Dermatology, Risk Assessment, Severity of Illness Index, Dermatitis, Atopic, [SHS]Humanities and Social Sciences, Cohort Studies, 030207 dermatology & venereal diseases, 03 medical and health sciences, Sex Factors, 0302 clinical medicine, Quality of life (healthcare), Sickness Impact Profile, Humans, Medicine, Sex organ, In patient, Prospective Studies, ComputingMilieux_MISCELLANEOUS, Reproductive health, [SHS.SOCIO]Humanities and Social Sciences/Sociology, business.industry, Age Factors, Atopic dermatitis, Middle Aged, medicine.disease, 3. Good health, Sexual desire, 030104 developmental biology, Infectious Diseases, Socioeconomic Factors, Quality of Life, Female, Sexual Health, business, Follow-Up Studies, Clinical psychology
Abstract: Background Sexual health is frequently affected by chronic diseases but has been poorly investigated in patients with atopic dermatitis (AD). Objective To evaluate the risk factors for impaired sexual desire and its relationship with the burden and quality of life of patients with AD. Methods A multicentre prospective transversal study in patients with AD. Socio-demographic and clinical data were obtained from all patients using a specifically developed questionnaire. In addition, patients were asked to answer validated scales, that is ABS-A, DLQI, SF-12 and EQ-5D. Results A total of 1024 patients participated in the study. Severity of AD, sites involved and treatment type was found to negatively impact the sexual desire of patients and their partners. In addition, the involvement of the genital and visible areas was associated with a higher burden and more significant alterations in quality of life. Conclusions The results of this study are substantial and clearly demonstrate the deep impact of AD on sexual health, its relationship with disease-related burden and alterations to quality of life. Psychosociological as well as neurosensory phenomena could help to understand these data.
Published: 2018
Full Text: View/download PDF

46. The impact of psoriasis on professional life: PsoPRO, a French national survey

Author: R. Aubert, P. Claudepierre, Yves Roquelaure, M. Lahfa, Pierre Levy, I. Bonnet, T Barnetche, Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Laboratoire d'Economie de Dauphine (LEDa), Université Paris Dauphine-PSL, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), Laboratoire d'Economie et de Gestion des Organisations de Santé (Legos), Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Service de rhumatologie, CHU Bordeaux [Bordeaux], Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Rhumatologie Bordeaux (SERVICE DE RHUMATOLOGIE), Centre de reference des maladies rares neuromusculaires, APHP, GH Henri Mondor, Creteil, Département de dermatologie, CHU Angers, Centre Hospitalier Universitaire d'Angers (CHU Angers), and PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)
Subjects: Adult, Male, Employment, medicine.medical_specialty, Population, Efficiency, Dermatology, Psoriasis/economics, 030207 dermatology & venereal diseases, 03 medical and health sciences, Psoriatic arthritis, 0302 clinical medicine, Cost of Illness, Surveys and Questionnaires, Internal medicine, Psoriasis, Absenteeism, Presenteism, medicine, Humans, 030212 general & internal medicine, Statistics & numerical data, education, ComputingMilieux_MISCELLANEOUS, Motivation, education.field_of_study, [QFIN]Quantitative Finance [q-fin], business.industry, Arthritis, Psoriatic, Case-control study, Middle Aged, Presenteeism, medicine.disease, JEL: I - Health, Education, and Welfare/I.I1 - Health/I.I1.I12 - Health Behavior, 3. Good health, JEL: I - Health, Education, and Welfare/I.I1 - Health/I.I1.I11 - Analysis of Health Care Markets, Infectious Diseases, Case-Control Studies, Sick leave, Female, France, Sick Leave, business, statistics & numerical data
Abstract: BACKGROUND The physical, social and mental burden of psoriasis is well known, but its occupational impact has been less investigated. OBJECTIVE To assess the impact of psoriasis on the working life of patients compared with the general population. METHODS A national survey compared people with and without psoriasis using online questionnaires. In addition to the demographic, medical and professional characteristics, data on recent absenteeism and presenteeism were captured using the validated WPAI-PSO questionnaire. RESULTS The patient sample comprised 714 with psoriasis (PsO), including 81 treated with systemic therapies (PsoST), and 84 with associated psoriatic arthritis (PsO + PsA). The control sample comprised 604 active subjects representative of the French population. Compared to controls, the impact of the disease on working life was no greater in PsO patients. Conversely, unemployment within the past 5 years and mean number of sick leaves within the previous year were more frequent in PsO + PsA. In patients with active psoriasis skin lesions, all aspects of the WPAI questionnaire were negatively impacted in PsoST and PsO + PsA patients, but not in PsO patients: Levels of absenteeism were 3.3% in controls, 5.6% in PsO (NS), 8.3% in PsoST (P
Published: 2018
Full Text: View/download PDF

47. Investigations upon the Improvement of Dermatophyte Identification Using an Online Mass Spectrometry Application

Author: Arnaud Jabet, Anne-Cécile Normand, Alicia Moreno-Sabater, Jacques Guillot, Veronica Risco-Castillo, Sophie Brun, Magalie Demar, Romain Blaizot, Cécile Nabet, Ann Packeu, Renaud Piarroux, Service de Parasitologie - Mycologie [CHU Pitié-Salpétrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Parasitologie - Mycologie [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Dynamic Microbiology - EA 7380 (DYNAMIC), École nationale vétérinaire - Alfort (ENVA)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Université Paris-Est (UPE)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Department of Parasitology and Mycology, Biopole d’Alfort, Ecole Nationale Vétérinaire d’Alfort (BIOPOLE - ENVA), École nationale vétérinaire - Alfort (ENVA)-Université Paris-Est (UPE), Centre Hospitalier Universitaire Vétérinaire – Faune Sauvage (CHUV-FS), École nationale vétérinaire - Alfort (ENVA)-Association Faune Alfort, Service de Parasitologie [Avicenne], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Sorbonne Paris Nord, Ecosystemes Amazoniens et Pathologie Tropicale (EPat), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Guyane (UG), Laboratoire Hospitalo-Universitaire de Parasitologie-Mycologie, Coordination Régionale de la lutte contre le Virus de L'Immunodéficience Humaine (COREVIH)-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-Université des Antilles (UA), Département de dermatologie [CH andré-Rosemont, Cayenne], Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Sciensano [Bruxelles], Réseau International des Instituts Pasteur (RIIP), and Gestionnaire, Hal Sorbonne Université
Subjects: [SDV.IB] Life Sciences [q-bio]/Bioengineering, MALDI-TOF, Microbiology (medical), dermatophytes, QH301-705.5, Plant Science, [SDV.MP.MYC] Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, MSI-2, Article, [SDV.IB]Life Sciences [q-bio]/Bioengineering, mass spectrometry, Biology (General), [SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, Ecology, Evolution, Behavior and Systematics
Abstract: International audience; Online MALDI-TOF mass spectrometry applications, such as MSI-2, have been shown to help identify dermatophytes, but recurrent errors are still observed between phylogenetically close species. The objective of this study was to assess different approaches to reduce the occurrence of such errors by adding new reference spectra to the MSI-2 application. Nine libraries were set up, comprising an increasing number of spectra obtained from reference strains that were submitted to various culture durations on two distinct culture media: Sabouraud gentamicin chloramphenicol medium and IDFP Conidia medium. The final library included spectra from 111 strains of 20 species obtained from cultures on both media collected every three days after the appearance of the colony. The performance of each library was then analyzed using a cross-validation approach. The spectra acquisitions were carried out using a Microflex Bruker spectrometer. Diversifying the references and adding spectra from various culture media and culture durations improved identification performance. The percentage of correct identification at the species level rose from 63.4 to 91.7% when combining all approaches. Nevertheless, residual confusion between close species, such as Trichophyton rubrum, Trichophyton violaceum and Trichophyton soudanense, remained. To distinguish between these species, mass spectrometry identification should take into account basic morphological and/or clinico-epidemiological features.
Published: 2022
Full Text: View/download PDF

48. Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma

Author: Lucie Peuvrel, Jean-Michel Nguyen, Edouard Chasseuil, Mélanie Saint-Jean, Brigitte Dréno, Amir Khammari, Emilie Varey, Gaëlle Quéreux, Hannah Chasseuil, Aurélie Gaultier, Département de Dermatologie [CHU Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Département de Dermato-Oncologie [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Clinical and Translational Research in Skin Cancer (CRCINA-ÉQUIPE 2), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Service d'Evaluation Médicale et d'Epidémiologie [CHU Nantes] (SEME), Bernardo, Elizabeth, and Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)
Subjects: 0301 basic medicine, Oncology, Male, Multivariate analysis, Skin Neoplasms, Time Factors, Neutrophils, Lymphocyte, Pilot Projects, Biomarkers, Pharmacological, Monocytes, Leukocyte Count, 0302 clinical medicine, Antineoplastic Agents, Immunological, Leukocytes, Medicine, Lymphocytes, Aged, 80 and over, Melanoma, Antibodies, Monoclonal, General Medicine, Middle Aged, 3. Good health, medicine.anatomical_structure, C-Reactive Protein, Treatment Outcome, 030220 oncology & carcinogenesis, Predictive value of tests, RL1-803, Female, France, Nivolumab, Adult, medicine.medical_specialty, Clinical Decision-Making, [SDV.CAN]Life Sciences [q-bio]/Cancer, Dermatology, Disease-Free Survival, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Predictive Value of Tests, Internal medicine, Biomarkers, Tumor, melanoma, Humans, predictive, anti-PD1, Aged, Proportional Hazards Models, Retrospective Studies, nivolumab, Performance status, L-Lactate Dehydrogenase, business.industry, Proportional hazards model, Patient Selection, Cancer, biomarkers, medicine.disease, 030104 developmental biology, Multivariate Analysis, pre- dictive, business
Abstract: Edouard CHASSEUIL and Mélanie SAINT-JEAN contributed equally and should be considered as first authors.; International audience; Nivolumab response rate is 40% in metastatic melanoma. Few studies have evaluated pre-treatment biomarkers predictive of response. The aim of this study was to identify potential peripheral blood biomarkers associated with survival in patients with advanced melanoma treated with nivolumab. All advanced melanoma cases treated with anti-programmed cell death protein 1 (anti-PD1) over a 3-year period in the Dermato-Oncology Department, Nantes, France were identified. For each case, 9 potential blood biomarkers were identified. Bivariate and multivariate analyses, adjusted for the American Joint Committee on Cancer (AJCC) classification stage, Eastern Cooperative Oncology Group (ECOG) performance status, lactate dehydrogenase (LDH) level and failure to respond to first-line therapy, were used to test the association between biomarkers and overall survival (primary outcome) or progression-free survival (secondary outcome). Increased monocyte count, leukocyte/lymphocyte ratio and neutrophil/lymphocyte ratio were significantly associated with decreased overall survival after bivariate and multivariate analyses. Increased monocyte count was also significantly associated with decreased progression-free survival. These blood variables are easily measured and could help to predict patient response before the introduction of anti-PD1 therapy.
Published: 2018
Full Text: View/download PDF

49. Age-Dependent Protective Effect of Selenium against UVA Irradiation in Primary Human Keratinocytes and the Associated DNA Repair Signature

Author: Anne-Marie Roussel, Walid Rachidi, E. Blouin, C. Favrot, M. T. Leccia, David Béal, Laboratoire Lésions des Acides Nucléiques (LAN), Service de Chimie Inorganique et Biologique (SCIB - UMR E3), Institut Nanosciences et Cryogénie (INAC), Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Institut Nanosciences et Cryogénie (INAC), Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Département de dermatologie, allergologie et photobiologie [Hôpital Michallon du CHU Grenoble Alpes], Centre Hospitalier Universitaire [Grenoble] (CHU)-Hôpital Michallon, Université Grenoble Alpes - UFR Pharmacie (UGA UFRP), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), SYstèmes Moléculaires et nanoMatériaux pour l’Energie et la Santé (SYMMES), Institut de Chimie du CNRS (INC)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Chimie Interface Biologie pour l’Environnement, la Santé et la Toxicologie (CIBEST ), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Centre National de la Recherche Scientifique (CNRS)-Institut Nanosciences et Cryogénie (INAC), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Centre National de la Recherche Scientifique (CNRS), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), and Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG)
Subjects: Adult, Keratinocytes, 0301 basic medicine, Aging, [SDV.BIO]Life Sciences [q-bio]/Biotechnology, Article Subject, DNA Repair, Ultraviolet Rays, DNA repair, Photoaging, chemistry.chemical_element, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.BC.BC]Life Sciences [q-bio]/Cellular Biology/Subcellular Processes [q-bio.SC], Biochemistry, Skin Aging, Selenium, Young Adult, 03 medical and health sciences, 0302 clinical medicine, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], [SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB], medicine, Humans, Uva irradiation, lcsh:QH573-671, Young adult, Cytotoxicity, Cells, Cultured, Aged, integumentary system, lcsh:Cytology, business.industry, Age Factors, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, Cell Biology, General Medicine, Middle Aged, medicine.disease, 030104 developmental biology, medicine.anatomical_structure, chemistry, 030220 oncology & carcinogenesis, Cancer research, Keratinocyte, business, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, Research Article
Abstract: International audience; Few studies have focused on the protective role of selenium (Se) against skin aging and photoaging even though selenoproteins are essential for keratinocyte function and skin development. To the best of our knowledge, the impact of Se supplementation on skin cells from elderly and young donors has not been reported. Therefore, the main objective of our study was to evaluate the effects of Se supplementation on skin keratinocytes at baseline and after exposure to ultraviolet A (UVA) irradiation. Low doses of Se (30 nM) were very potently protective against UVA-induced cytotoxicity in young keratinocytes, whereas the protection efficiency of Se in old keratinocytes required higher concentrations (240 nM). Additionally, the DNA repair ability of the old keratinocytes drastically decreased compared with that of the young keratinocytes at baseline and after the UVA exposure. The Se supplementation significantly enhanced the DNA repair of 8-oxoguanine (8oxoG) only in the keratinocytes isolated from young donors. Therefore, aged keratinocytes have an increased vulnerability to oxidative DNA damage, and the Se needs in the elderly should be considered. Strengthening DNA repair activities with Se supplementation may represent a new strategy to combat aging and skin photoaging.
Published: 2018
Full Text: View/download PDF

50. Adult female acne treated with spironolactone: a retrospective data review of 70 cases

Author: Mélanie Saint-Jean, Elodie Boisrobert, Brigitte Dréno, Amir Khammari, Jean-Michel Nguyen, Anne Isvy-Joubert, Aurélie Gaultier, Marie Le Moigne, Département de Dermatologie [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Clinical and Translational Research in Skin Cancer (CRCINA-ÉQUIPE 2), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Unité méthodologique [CHU Nantes] (Département de recherche clinique), Bernardo, Elizabeth, and Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)
Subjects: medicine.medical_specialty, medicine.drug_class, [SDV.CAN]Life Sciences [q-bio]/Cancer, Dermatology, Severity of Illness Index, Retrospective data, Young Adult, 030207 dermatology & venereal diseases, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Risk Factors, Internal medicine, Acne Vulgaris, Androgen Receptor Antagonists, medicine, Humans, 030212 general & internal medicine, acne, Isotretinoin, Acne, Retrospective Studies, Back, Adult female, Proportional hazards model, business.industry, adult, isotretinoin, Middle Aged, medicine.disease, Dermatitis, Seborrheic, progestin, 3. Good health, Surgery, Androgen receptor, Treatment Outcome, spironolactone, female, contraception, chemistry, Spironolactone, Dermatologic Agents, Progestins, business, Progestin, Facial Dermatoses, Contraceptives, Oral, medicine.drug
Abstract: International audience; The prevalence of acne in the adult population is increasing, particularly in women. Spironolactone regulates sebaceous gland activity by blocking androgen receptor. To evaluate retrospectively the efficacy of spironolactone in women with acne. Data from 70 women of at least 20 years, treated for their acne between 2010 and 2015 with low-dose spironolactone (≤150 mg/day), were analysed. Remission was defined by the number of retentional lesions inferior or equal to five and inflammatory lesions inferior or equal to two on the face. Variables influencing the response were studied using the Cox model. The mean age was 31.3 years; 39 (56%) women had prior courses of isotretinoin and 53 (76%) had an oral contraception prior to treatment. Remission data from a median treatment period of six months (95% CI: 4-9) were obtained from 47 (71%) women. Markers for a positive response to spironolactone were a high number of inflammatory lesions at inclusion (OR: 1.08; 95% CI: 1.03-1.13; p = 0.001) and relapse with previous isotretinoin (OR: 2.46; 95% CI: 1.09-5.54; p = 0.03). The marker for a negative response was an association with oral contraceptives containing first or second-generation progestin (OR: 2.77; 95% CI: 1.35-5.71; p = 0.005). This retrospective data analysis confirms that the use of low doses of spironolactone is a valuable alternative in women with acne in whom oral isotretinoin has failed. Moreover, the analysis shows that first and second-generation oral contraceptives decrease the efficacy of spironolactone, confirming the interest of using two third or fourth-generation oral contraceptives.
Published: 2017
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

772 results on '"Département de Dermatologie"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources